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ABSTRACT
Background:
The management of pain in children is a common but difficult symptom to treat and the 
use of strong analgesics is often limited, for a variety of reasons, including fear of 
inducing side effects. Morphine is normally considered to be a centrally acting analgesic 
but recently, the beneficial effects of peripheral opioids have been demonstrated in 
adults for a number of painful inflammatory conditions. When administered in this non- 
invasive way, opioids provide analgesia without achieving significant plasma 
concentrations and therefore it can be assumed that many of the adverse effects 
associated with oral or systemic opioids are avoided.
Methods:
A) The first part of the thesis describes the mechanism of action of peripheral opioids 
through development and particularly their effect during inflammation. This work was 
conducted using different ages of Sprague Dawley rat pups and skin inflammation was 
induced using carageenan.
B) The second section is a description of a double-blinded, randomised-controlled, 
placebo-controlled trial with crossover design, to assess the efficacy of peripheral 
opioids in paediatric inflammatory pain. This was conducted in children with a 
diagnosis of Epidermolysis Bullosa (EB), as a model for acute and chronic 
inflammatory pain
Results:.
The laboratory study demonstrates that mu opioid receptor (MOR) expression is up 
regulated in neonatal plantar skin and significantly up regulated in neonatal lumbar 
dorsal root ganglion (DRG) four hours post hind paw inflammation, MOR protein levels 
in the rat hind paw plantar skin are significantly up regulated post-natally, and MOR 
protein levels are significantly up regulated in both neonatal and young adult plantar 
skin four hours post hind paw inflammation. Clinically, pain reduction was most 
significant with background pain
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Conclusion:
The developmental regulation of peripheral MOR both in naive and inflamed cutaneous 
tissue may have implications for the use of topically / peripherally applied opioids in 
infants and children.
“I, Gillian Watterson confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated 
in the thesis”.
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CHAPTER 1
1.1 GENERAL INTRODUCTION
Pain is a complex and multi-dimensional symptom, which we all experience at some 
time in our lives. Under-treatment of pain can lead to long-lasting catastrophic effects 
both physiological and psychological. Fortunately, much has changed in the field of 
paediatric pain research since the initial reports of inadequate pain management in 
infants and children documented well over 25 years ago (Swafford and Allan 1968). 
Although laboratory research has now revealed the precise pain mechanisms, 
demonstrating that even the youngest infant is capable of painful experiences and 
therefore in potential need of analgesia (Fitzgerald et al 1988), there is still a gap 
between this knowledge and implementation in the clinical setting. Strict ethical 
processes exist, particularly for clinical trials involving children and yet there is a 
pressing need for research, especially in the areas of pain assessment, management of 
neuropathic and persistent pain states in children as well as the introduction of novel 
analgesics.
Traditionally opioids act through the central nervous system but studies in the adult 
population have now characterised definite peripheral actions of opioids upon peripheral 
morphine receptors (MOR), providing both anti-nociceptive and anti-inflammatory 
effects (Stein et al 1991, Krajnik and Zylicz 1997; Flock et al 2000; Stein et al 2001). 
This exciting development of opioid receptor pharmacology could potentially lead to 
effective analgesia when opioids are applied to peripheral tissues, but without the 
centrally mediated and often intolerant adverse effects.
My research, both a laboratory and clinical project, has attempted for the first time to 
provide evidence for the existence of peripheral opioid receptors throughout 
development in skin tissue, from the neonatal period onwards. It also explores whether 
inflammation might have an effect on the quantity of receptors (chapter 3). The second 
part of the thesis is clinical work exploring the efficacy of a novel route of peripheral 
opioids in a paediatric population (chapter 4).
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Layout of thesis:
The thesis is divided to two main sections:
A) Laboratory study The first part of my thesis describes various studies carried out in 
the Department of Anatomy and Developmental Biology laboratory, University College 
London. This work focuses on the existence of peripheral opioid receptors throughout 
development and whether there is any alteration in receptor number following an 
inflammatory painful insult, using immunofluroescence and light microscopy, as well as 
quantification of the MOR protein using Western Blot technique. The skin tissue of rat 
pups are used in these studies.
B) Clinical study The second part explores the efficacy and use of topical (peripheral) 
opioids in children and young people with Epidermolysis Bullosa (EB). EB is a group 
of inherited mechano-bullous disorders involving blistering of the skin and mucous 
membranes, in response to minor frictional trauma. I focus on one of its main symptoms 
namely pain, because different sub-types of pain are experienced in EB patients and it 
is therefore an extremely useful model for the purpose of this work (Herod et al 2002). I 
have not included details of the patho-physiology or management of the disorder. 
Previous studies investigating peripheral opioids, have only been carried out in the adult 
population and have recruited mainly a population of patients who are in the palliative 
phase of their illness and who have experienced a varying range of cutaneous lesions, 
triggering episodes of either acute inflammatory pain, acute incident pain, chronic 
inflammatory pain, neuropathic pain or indeed a combination of these pain types 
(Krajnik and Zylicz 1997; Twillman et al 1999; Flock 2003; Zeppetella et al 2003). 
This study focuses on the use of topical morphine and its efficacy particularly in 
incident pain, background inflammatory pain and post-procedural pain in a paediatric 
patient group.
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In order to understand the neurobiology, physiology and classification of pain in the 
developing human, I will first document the commonly used definition of pain and 
summarise how important historical theories have provided a foundation for our current 
knowledge, of pain and its mechanisms in the human adult.
1.2 PAIN DEFINITION
The International Association into the Study of Pain has defined pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage.” 
This definition encompasses both the physical and emotional perception of pain, rather 
than considering the actual amount of tissue damage leading to the pain i.e nociception 
(IASP Taskforce on taxonomy 1994).
However considering the diverse and individual nature of pain experiences, the above 
definition is not suitable to be applied in all situations; e.g. in the preverbal child or the 
cognitively impaired. The relationship of the perception to the stimulus is variable and 
depends on the patient’s previous experiences, emotional state and cognition. In 
particular relation to pain in neonates and infants, it is also necessary to consider the 
development of sensory pathways as well as development of consciousness and the 
mind.
1.3 PAIN THROUGH THE CENTURIES
The first mechanism of pain perception was suggested by Descartes almost four 
centuries ago 1664 - he stated that pain was “fast moving particles o f fire., the 
disturbance passes along the neurofilament until it reaches the brain”. This simply 
described the concept that the pain system was a direct channel from the skin to the 
brain. He stated that a flame sets alight particles in the foot into motion up the leg and 
back and into the head where an alarm system is then set off, causing the person to feel 
pain (Descartes 1664).
In the nineteenth century, Max Von Frey, physician proposed that specific pain 
receptors in the body project via pain fibres to a pain centre within the central nervous 
system. His second suggestion was that below each sensory spot in the skin lay a 
specific receptor, linked to each of the four sensory modalities but this has never been 
proven.
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However a final proposal which was accepted was the pattern theories of pain, which 
suggests that painful information generated by peripheral skin receptors is coded in 
patterns of nerve impulses (von Frey 1894).
In 1965 the Melzack and Wall Gate Control Theory was published in Science entitled a 
“A New Theory of Pain”. Simply speaking it stated that pain transmission from the 
peripheral nerve through to the spinal cord was subject to both intrinsic controls and 
controls originating from the brain. Melzack and Wall proposed that the perception of 
pain depends not only upon pain signals in small fibres, but also upon the balance of 
activity in large myelinated fibres (A-alpha and A-beta fibres) and small myelinated and 
unmyelinated nociceptive fibres (A-delta and C fibres). They hypothesised that under 
normal conditions, any stimulus which increases the activity of the large 
mechanoreceptive fibres tends to reduce pain, and anything that increases the activity of 
small nociceptive fibres tends to increase pain (Melzack and Wall 1965), (See Fig 1.1). 
However they failed to include the peripheral processes involved in pain.
For example, when there is tissue damage and inflammatory pain ensues, there is a 
peripheral inflammatory soup of chemical mediators released which sensitise the 
peripheral sensory nerve endings and following neuropathic pain, excitability changes 
occur within the peripheral nerves themselves. Both of the above peripheral 
mechanisms then cause change within the central pain systems (McMahon et al 1993). 
Pain as a symptom continues to emerge as a complex sensory modality, initiating from 
Descartes’ basic linear theory, to the current theories based on Wall’s Gate Theory.
14
Higher Centres in Brain
1
©
©
Ap Fibre
A8 Fibre 
AC Fibre
Key: Inhibitory Intemeurone + inhibition - excitation
Projection Interneurone
1. Explanation: When there is no simulation, all pain fibres are inactive and the inhibitory 
intemeuron blocks the signal in the projection neuron. The gate is therefore closed and 
no pain is experienced.
2. With a noxious stimulus, A5 and AC fibres are activated, which in turn stimulate the 
projection neuron and blocks the inhibitory neuron. The gate is open and there is pain.
3. When a non- painful stimulus such as touch is experienced, the Ap fibres are stimulated 
and activates the projection neuron as well as the inhibitory neurones which in turn 
blocks the projection neuron which connects to the spinothalamic tract ascending to the 
pain centres in the brain and no pain is experienced
Fig 1.1 Basic Diagram explaining the Gate Control pain Theory
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1.4 TYPES OF PAIN IN CHILDREN
1.4.1 Classification
I will first discuss a simple pain classification system and then will follow on with a 
description of the more commonly known pain mechanisms.
There are several ways to categorise pain in both adults and children but broadly 
speaking there are two major divisions; Acute and Chronic pain.
Acute pain as a response to tissue injury, is where healing will occur thus protecting the 
patient from further injury and the pain usually decreases steadily over time. Acute 
nociceptive pain, is a normal predicted physiological response to an adverse chemical, 
thermal or mechanical stimulus such as that associated with trauma, surgery, and acute 
illness. It occurs when there is an alteration in the nociceptor properties but usually 
resolves as the tissue damage begins to subside and healing is initiated. It is a protective 
pain, in that the patient is protected from further tissue damage. There is normal neural 
transmission. Post- operative pain in children may be used as an example to 
demonstrate the various immediate neurochemical and neurophysiological responses, as 
well as longer term psychological effects.
Acute pain may arise from tissue damage following an inflammatory insult, such as in 
bums. Juvenile rheumatoid arthritis is a classic example of inflammatory pain, where an 
influx of immunocytes, such as mast cells and macrophages release excitatory 
neurotransmitters in response to a noxious stimulus and subsequent tissue damage.
Chronic or persistent pain was previously defined by the International Association for 
the Study of Pain (IASP 1986), as pain which is constant for 6 months or longer, but it 
has now become clear that there are elements of chronic pain which may actually arise 
much earlier and the revised classification is now pain less than 1 month, 1 to 6 months 
or longer than 6 months (IASP Subcommittee on Taxonomy 1994).
This may be a result of prolonged acute pain secondary to an underlying organic 
disorder such as a tumour, a skeletal dysplasia or in arthritis, where there are repeated 
inflammatory episodes such as in those patients with EB.
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It can be distinguished from recurrent pain syndromes where there are alternate periods 
of painful and pain free episodes, for example in chronic recurrent headaches or in the 
recurrent abdominal pain syndrome.
Chronic pain may also exist where there is no underlying pathological cause. Possible 
predisposing factors are female gender, hypermobility, maladaptive coping strategies, 
and parental modelling of pain behaviours.
Unfortunately this pain may go unrecognised for years and may progress to a pain 
disability syndrome affecting the child’s physical, emotional and psychological coping 
mechanisms (Zeltzer et al 1997). Sleep disturbance is often a huge problem for these 
patients as well as school absenteeism. It is believed that for some of these patients, 
there is reinforcement of the sick role and apparent pain amplification (Eccleston 2003).
Neuropathic Pain is a characteristic type of pain which persists independent of 
ongoing tissue damage or inflammation. It may be acute or chronic and is due to an 
altered excitability of the peripheral, central or autonomic nervous system (Bennett
1997). It is generally not protective and usually persists even though the original 
noxious stimulus has subsided. There are a range of particular sensory disturbances such 
as allodynia (a pain response secondary to a non-noxious stimulus) and hyperalgesia 
(heightened pain response to a painful/thermal or mechanical stimulus) as well as motor 
disturbances such as weakness and spasms and autonomic symptoms such as cyanosis, 
sweating and swelling of the affected site (Devor 1984). This subtype of pain occurs in 
such conditions as the Complex Regional Pain Syndromes (Wilder et al 1992), 
secondary to tumour compression or tumour therapies, in phantom limb pain 
(Wilkins et al 1998) or in diabetic patients who have ulcerative lesions as well as 
peripheral neuropathy.
Breakthrough Pain The terms, breakthrough /episodic and incident pain are often 
confused. Breakthrough pain was initially described by Portenoy and Hagen (1990) 
following a study on cancer patients, as a “transient increase in the intensity of moderate 
or severe pain, occurring in the presence of well-established pain.”
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Just over a decade later, the American Pain Society (2005) consolidated the definition 
as “intermittent exacerbations of pain that can occur spontaneously or in relation to 
specific activity; pain that increases above the level of pain addressed by the ongoing 
analgesic; includes incident pain and end-of-dose failure.”
Incident pain is the description traditionally given to pain which may occur on 
movement, for example coughing/vomiting or whilst walking.
There is also a subtype of incident pain unrelated to motion and occurs when the patient 
is at rest with no known triggering factor. These pains are episodic in nature such as 
secondary to spasms. Incident pain may therefore be acute or chronic depending o the 
disease progress and treatment given. Management of breakthrough pain is 
straightforward and requires regular review and alteration of medication and dosage. 
However it is more difficult to achieve adequate control of incident pain and requires an 
individualised approach of balancing efficacy of each drug against adverse effects 
(McQuay 1989).
1.5 MECHANISMS OF PAIN
Several types of pain are now recognised and the complex mechanisms behind such 
pains are becoming clearer. The following mechanisms will now be discussed in more 
detail:
A) nociception
B) peripheral sensitisation
C) phenotypic switches
D) central sensitisation
E) neuropathic pain mechanisms
A) Nociception
Nociception is the detection of a painful noxious stimulus and it encompasses the entire 
process from the actual site of active tissue damage, through to the cortical perception 
of pain via a complex array of physiological and biochemical events. It involves four 
major processes:
• transduction
• transmission
18
• modulation
• perception
Transduction
Transduction involves relaying the specific noxious physical and chemical stimuli to the 
spinal cord, once they have been converted into electrical impulses, at the peripheral 
terminals of nociceptor sensory fibres.
These terminals are known as primary afferent nociceptors and give rise to sensory 
fibres, which possess characteristic properties, distinguishing them from other sensory
nerve fibre. The table below, (table 1.1) summarises the properties of these nociceptors:
Adelta (A 5) Abeta ( A P ) C
finely myelinated, small 
fibres
large, myelinated unmyelinated, small cell 
bodies
rapid firing -  10-40 m/s rapidly conducting j slow rate < 2 m/sec
sharp ; first acute pain transmit innocuous 
information
i1
! dull; second pain
j
; mechanothermal 
i  mechanosensitive
respond to touch, 
vibration,deep pressure
polymodal receptors- 
respond to
thermal,mechanical and 
chemical noxious
Table 1.1 Properties of Primary Afferent Nociceptors
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Transmission
Transmission is the propagation of an impulse from neuron to neuron throughout the 
sensory nervous system, by primary afferent neurons which synapse in the dorsal horn 
of the spinal cord. Afferent fibres enter the spinal cord and travel via Lissauer’s tract 
before sending processes into the dorsal horn. A5 fibres synapse in laminae 1 and 5, C 
fibres synapse in laminae 1 and 2 (substantia gelatinosa) and Ap fibres synapse in 
laminae 3, 4, 5 and 6. (See Table 1.1 for the properties of these fibres).
Then this process activates projection neurons, either directly of via intemeurons, which 
then cross over the midline and ascend to the brainstem and thalamus. These fibres 
along with the second order neurons, form the spinothalamic tract, the major ascending 
pathway for pain and temperature.
Modulation
Modulation is the process of both attenuation and amplification of the initial noxious 
signal. It occurs between pathways of descending inhibition originating within the 
somatic sensory cortex, the hypothalamus, the periaqueductal gray matter of the 
midbrain, the raphe nuclei and other nuclei of the rostral ventral medulla. Complex 
modulatory effects occur at each of these sites as well as in the dorsal horn. Both 
excitatory and inhibitory neurotransmitters are involved.
Descending pathways release transmitters such as 5HT, noradrenaline, and endogenous 
opioids to produce inhibitory control. At the spinal cord level, there are classes of 
intemeurons which contain one or more peptides such as enkephalins or inhibitory 
amino acids such as GABA and glycine. Overall these neurotransmitters aim to act 
upon inhibitory interneurons, thus causing a decrease in pre and postsynaptic activity, or 
excite the second order neuron, producing descending excitation.
Perception of Pain
Pain is a complex phenomenon not only involving the transduction of a noxious 
stimulus but also cortical processing, which then determines the individual 
perception of pain.
Pain perception is largely a cognitive process influenced by physiological, 
neurochemical, contextual, emotional and behavioural variables.
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Cognitive factors affect pain perception at all ascending neural levels of pain, from 
transmission of nociceptor input, through to thalamic and cortical pathways. Perception 
of pain depends not only on the extent of the physical injury, but also on a series of 
complex interactions, where modification of the nerve impulses which have been 
generated by tissue damage and it occurs by means of ascending systems and 
descending pain suppressing systems.
B) Peripheral sensitisation
Tissue damage at the periphery, following a noxious stimulus, triggers the release of 
peptides such as substance P as well as serotonin, histamine, in combination with the 
involvement of inflammatory cells, which then forms an “inflammatory soup”. This 
directly activates and sensitises peripheral nerve endings to cause pain, swelling and 
tenderness, secondary to vasodilatation and plasma extravasation (Dray 1997).
Primary hyperalgesia may develop from the above process around the area of tissue 
damage so non-noxious stimuli seem painful (allodynia) and noxious stimuli produce an 
even more heightened pain response (hyperalgesia).The entire process of chemical 
signalling, which arises from local damage, not only protects the damaged area, but also 
promotes healing and helps to prevent infection, due to the increased blood flow and 
inflammation.
C) Phenotypic changes
Following tissue injury and inflammatory pain, transport of neurotransmitters from the 
periphery to the dorsal root ganglion activates intracellular pathways, which then alter 
the properties of sensory neurons, e.g. in neuropathic pain, changes in the phenotypic 
expression of sodium and potassium channels post nerve injury lead to 
hyperpolarisation of the membrane (Amir et al 2006).
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D) Central Sensitisation
This is characterised by reduction in threshold and an increase in responsiveness of 
dorsal horn neurons, as well as enlargement of their receptive fields and sensitivity to 
non- noxious stimuli (allodynia and secondary hyperalgesia ).During central 
sensitisation in the dorsal horn, there is a repeated constant C fibre stimulus which can 
induce an augmented response to subsequent C fibre input - “wind up.” This leads to an 
intense acute pain secondary to closely repeated stimuli.
The NMDA (N methyl-D- aspartate) receptor is required for this amplification, as well 
as activation of other ion channels such as the AMPA (amino hydroxy methyl isoxazole 
proprionic acid) receptor, the neurokinin receptor and tyrosine kinase receptors 
(Dickenson and Beeson 1997).The release of peptides such as substance P into the 
spinal cord, removes the magnesium block from the channel of the NMDA receptor and 
permits glutamate to activate the receptor into a persistent pain state (De Felipe et al
1998). Also activation of the NMDA receptor allows calcium to enter the neurone, 
which leads to further production of other mediators from spinal neurones contributing 
to the overall process.
E) Neuropathic Pain mechanisms.
A combination of the above pain mechanisms may exist in the syndrome of 
neuropathic pain. Human studies have demonstrated that A fibre activity leads to 
neuropathic pain, more specifically the touch evoked allodynia, while burning 
spontaneous pain is probably maintained via C nociceptors. Peripheral sensitisation has 
been shown in certain neuropathic pain states such as post-herpetic neuralgia, where C 
fibre sensitisation has been shown to induce touch evoked Ap allodynia (Chabal 1989). 
Axon damage in the adult also leads to a change in the function, structure and 
phenotypic expression of cell bodies within the dorsal root ganglion including opioid 
peptide receptor and glutamate receptor expression (Alvares and Fitzgerald 1999, Woolf 
and Mannion 1999). This may be due to loss of peripheral neurotrophic influences.
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It has also been demonstrated that spontaneous ectopic discharges within the DRG can 
occur after nerve section, as well as accumulation of sodium channels at the axotomy 
site, which then may lead to a hyperalgesic, persistent pain state (Amir et al 2006). 
Centrally, following adult axotomy, there is a synaptic rearrangement whereby Ap 
fibres, which normally occupy Laminae 3 and 4, sprout up to Laminae 1 and 2 and thus 
contributing to allodynia (Shortland and Woolf 1993).
Central sensitisation including the wind-up phenomenon are the hallmarks of 
neuropathic pain but advances in molecular studies as well as functional imaging have 
led to the introduction of novel clinical therapies in an attempt to manage this complex 
pain state.
1.6 THE DEVELOPMENT OF PAIN PROCESSING IN NEONATES AND 
INFANTS
1.6.1 Introduction
Table 1.2 documents the neurodevelopment of human pain pathways.
Until very recently, it was the common belief that neonates and even infants did not 
have the ability to experience or even to remember early painful events. Under 
treatment of pain in children occurs because of the following common misconceptions 
and views held about infant and paediatric pain which include (Schechter and Allen 
1986, McGrath and Finley 1996).
a) The nervous system of the infant is immature.
b) Active children are not in pain.
c) Children always report their pain.
d) Children cannot reliably describe or locate their pain
e) Parent’s are the best reliable source of their child’s pain
f) Analgesics are not safe in infants and children.
g) Psychological intervention such as cognitive therapy is not effective in reducing 
children’s pain.
h) Fear of adverse effects using stronger analgesics such as opioids.
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A major source of under treatment is lack of knowledge and awareness amongst 
medical professionals, concerning the mechanisms of children’s pain. Until fairly 
recently, there have been a lack of paediatric textbooks and other teaching materials, 
which focus specifically on the management on pain in children (Rana 1987).
In view of these factors, pain in the clinical setting has been under recognised and under 
treated and coupled with inappropriate fears of increased adverse effects from strong 
analgesics such as opioids, even many surgical and other invasive procedures, such as 
chest drain insertion and removal have been performed without analgesia (Barker and 
Rutter 1995).
However now, due to well conducted laboratory and clinical research, it is more widely 
accepted that infants not only experience pain, but possibly even more acutely than the 
adult population (Fitzgerald and Koltzenburg 1986; Anand 2000).
1.6.2 Neurodevelopment of pain pathways (Table 1.2)
It is practically impossible to study pain in children, particularly the neonatal age group 
mainly due to ethical reasons. Animal models have been therefore been developed and 
because of the similarities in the pain systems of the rat and human the neonatal rat pup 
is the most frequently accepted model for understanding the neurodevelopment of the 
pain pathways. Some of the principle similarities between the two species include;
• neurotransmitters released in response to pain (Anand 1999; Marti et al 1987)
• large receptive fields in the dorsal horn (Yi and Barr 1995)
• presence of functional C polymodal receptors ( Fitzgerald 1987)
• immature descending inhibitory systems ( Fitzgerald and Koltzenburg 1986)
• exaggerated cutaneous reflexes ( Fitzgerald et al 1988)
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Table 1.2 Neurodevelopment of human pain pathways
(Puchalski et al 2002)
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The following Tablel.3 gives a guide to the age equivalents of rats and humans 
(Anand 2000) but it is it is still important take into account the differences in 
complexity between the human and rodent central nervous system , in particular the 
cognitive and emotional development of the human neonate.
Table 1.3 Age of rat pups and equivalent human age
Age of rat pup Equivalent human age
P0 24 weeks
P7 Full term
P14 1 year old
P21 Toddler
The nervous system at birth exhibits a much greater hypersensitivity to various stimuli 
in comparison to the adult. The developing human neonate’s central nervous system 
(CNS) demonstrates plasticity, that is the ability to be moulded or reformed. This may 
be beneficial, as an enriched environment may assist the neonate to remodel his brain 
with a regeneration of neurons and consequently they have the ability to recover more 
readily from cortical results. Conversely, persistent pain during the neonatal period may 
have permanent detrimental consequences on long- term nociceptive neuronal 
development (Woolf and Salter 2000).
It is now known that pain experienced in the neonatal period will be remembered by this 
ever-changing nervous system for a long time and lead to permanent alterations within 
the neural circuits, therefore strategies aimed at reducing or abolishing these early pain 
experiences are essential (Ruda et al 2000).
1.6.3 Long -term effects of neonatal and infant pain
There are now a series of elegant laboratory studies which illustrate the long-lasting 
changes (cellular, neurophysiological and behavioural) that ensue both centrally and 
peripherally, following neonatal noxious insults (Fitzgerald and Swett 1983; Fitzgerald 
1985; Fitzgerald and Koltzenburg 1986; Alvares et al 2000).
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Following repeated painful insults, it has also been demonstrated there are changes in 
the central and peripheral pain systems in the neonate rat pup and it is becoming more 
evident that these early pain experiences will have an impact on the developing nervous 
system and lead to permanent alterations (Anand 1999).
1: Spinal and supraspinal changes. Repetitive stimulation leads to “wind up”, where 
there are lower thresholds to any further stimuli and due to the larger receptive fields, 
any weaker noxious stimuli actually produce exaggerated responses. It has also been 
demonstrated that there is an immature descending inhibitory pain system as well as 
lack of neurotransmitters ( Fitzgerald and Koltzenburg 1986) and even some inhibitory 
mediators nay actually be excitatory in the neonate such as glycine and GABA 
contributing to the increased susceptibility of neonates and infants to experience an 
heightened pain response.
2: Peripheral changes : The number of sensory neurons responding to pain depends on 
neurotrophic factors such as nerve growth factor (NGF), which also determines skin 
innervation. If there has been a series of noxious insults to the skin at birth, then an 
increase in NGF exists leading to skin hyperinnervation and sprouting of cutaneous 
nerve fibres (Reynolds et al 1997).The laboratory studies conducted to study the effects 
of long- term pain include neonatal rat pups who had 4 daily needle pricks during the 
first week of life and were more hypersensitive to pain at 16 and 22 days (Anand 1999).
Neonatal rat pups who had local inflammatory pain for 5-7 days, had an increase of 
sensory fibres which formed connections with the laminae 1 and 2 as well as caudally 
L5/S1, where there is usually no sensory input. The dorsal horns were then noted to be 
hyperexcitable at rest and led to an overall increased pain response (Ruda et al 2000). 
Behavioural studies showed that neonatal rats who were exposed to repeated noxious 
stimuli grew up to be adults who had withdrawal behaviours, increased alcohol 
preference as well as decreased latencies to heat showing that they may have an altered 
ability to cope and deal with stress (Anand 1999).
27
In human infants, following a series of brief noxious stimuli (heel lances), it has been 
demonstrated, using the cutaneous withdrawal reflex, that responses are not as 
discriminative, more exaggerated, with larger receptive fields, lower threshold and 
therefore increased sensitivity and with a tendency to hypersensitivity (Andrews and 
Fitzgerald 1994) .This threshold was half that of the contralateral heel which led to 
hypersensitivity but that this could be prevented with the local anaesthetic cream EMLA 
(Fitzgerald et al 1988).Those infants who have been in the neonatal intensive care unit 
requiring repeated painful tests displayed an immature facial response following each 
procedure (Johnson and Strada 1986).
It has been shown that full-term neonates, who underwent circumcision without any 
anaesthetic, had an associated heightened pain response at 4-6 months post operation 
during their routine immunisations. This hypersensitivity was partially reduced with 
application of a local anaesthetic during circumcision (Taddio et al 1997).
A subsequent patient group which included full term neonates of diabetic mothers, who 
required repeated heel lances in the first 36 hours of life, demonstrated a greater pain 
response than normal infants and learned to anticipate pain, with subsequent noxious 
stimuli (Taddio et al 2002). Even though they may not consciously recall their early 
painful experiences, it has been suggested that they may be more likely to display 
abnormal behavioural patterns or altered sensory processing in later life (Grunau and 
Craig 1987).
In summary, repeated noxious stimuli experienced in the fetal of neonatal period may 
lead to permanent changes within the adult pain sensory system such as;
• skin hyperinnervation
• increased skin nerve sprouting
• hyperexcitable sensory neurons within dorsal horns which cause adaptive 
changes causing an overall hypersensitivity and susceptibility to pain
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1.7 MANAGEMENT OF PAIN IN CHILDREN
Recently, there has been an increase research into the study of the safety, efficacy, 
pharmacokinetics, pharmacodynamics and clinical outcomes associated with a variety 
of analgesics for children. (Berde and Sethna 2002).
The best method of managing acute pain is with a combination of both pharmacological 
and non-pharmacological approaches using protocols for specific use in the paediatric 
patient group.
The World Health Organisation guidelines recommend an analgesic ladder approach, 
which emphasises the initial use of simple analgesics such as paracetamol, then 
proceeding to stronger analgesics, such as codeine and then finally strong opioids, 
although the terms “weak opioids and adjuvants” are rather ambiguous in the current 
environment of advancing analgesic pharmacology (WHO 1990). It is intended to 
provide a basic pathway for pain management. This ladder was initially introduced for 
management of pain in adult cancer patients with little adjustment for paediatric or non- 
malignant pathology.
There are 4 basic concepts summarising the ladder approach in relation to children;
• by the ladder
• by the clock
• by the appropriate route
• by the child
There are questions surrounding the use of the ladder in other diagnoses such as non- 
malignant pain other than cancer and although it has not been formally validated for 
these conditions, it is generally widely accepted that the principles of the step wise 
analgesia ladder may be applied (Fig 1.2 ).
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Increasing pain intensity
Strong opioid 
+Non- opioid
+/-adjuvants STEP 3
Weak opioid 
+ Non-opioid
+/-Adjuvants STEP 2
Non-opioid 
+/ - Adjuvant
STEP 1
Fig 1.2 WHO Analgesic Ladder: The World Health Organisation Analgesic Ladder 
has provided an excellent framework for the escalation of analgesia for many years. A 
more flexible approach is now advocated, particularly for children’s pain with 
management strategies customised according to the child's pain, the mechanism 
involved, the child's particular needs and response to previous treatments. The entry 
level onto the ladder will be influenced by these factors. Treatment should be frequently 
reassessed and modified. An adjuvant analgesic agent can be added at any point on the 
ladder if  indicated by the clinical circumstances eg. bone pain, neuropathic pain, 
inflammatory pain. (The World Health Organization 1998). The addition o f non­
steroidal anti-inflammatory drugs (NSAIDs) and co-analgesics should be considered at 
any stage throughout the treatment process.
A variety of analgesics are available, but oral paracetamol is the most widely used 
analgesic for children. It is a safe drug with a potential of becoming toxic in a few states 
including fever, dehydration or hepatic impairment.
Its mechanism of action involves central blockade of cycloxygenase with little 
peripheral effect and so it possesses no anti-inflammatory properties.
It is not however as effective for procedural pain such as venepuncture (Lesko and 
Mitchell 1999).
Non- steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen inhibit 
cyclooxygenase in the spinal cord and periphery and are analgesic as well as antipyretic. 
Ibuprofen is the most commonly used NSAID in children and has a synergistic effect 
with paracetamol. It is very effective in inflammatory juvenile arthritis and peri- 
operatively (Romsing and Walther-Larsen 1997). Both paracetamol and the NSAIDs 
have a ceiling effect and may also be opioid sparing (Korpela et al 1999). Adverse 
effects of NSAIDs such as gastrointestinal bleeding secondary to platelet dysfunction, 
peptic ulcer formation and nephrotoxicity need to be monitored in children, especially 
those requiring regular use (Lesko and Mitchell 1999). Paracetamol and NSAIDs such 
as ibuprofen are particularly useful in combination with each other for mild to moderate 
pain especially if there is bony pain, such as arthritis (Williams et al 1986).
Paediatric protocols have now been devised for the safe use of opioids and experience 
with analgesic use in children is improved. Opioids are discussed in greater detail in the 
following chapter.
For acute procedural pain in children, local topical anaesthetic agents, EMLA / Ametop 
are effectively used for short procedures such as venepuncture (Gunter 2002).
The combination of therapeutic agents and cognitive behavioural strategies such as 
guided imagery or visualisation should always be encouraged in children undergoing 
acute procedures (Kuttner et al 1988). Patient controlled analgesia may be used in 
children greater than 5 years for administering opioids or ketamine and in adult patients, 
local nerve blocks and epidural anaesthesia for acute pain post-operatively, have been 
studied, confirming their safety and efficacy (Monitto et al 2000).
Most research in chronic pain syndrome management in the paediatric and adolescent 
population has focused on the use of a multidisciplinary rehabilitation programme.
There are different models worldwide; for example some require the child and a family 
member to be residential for a period of up to three weeks (Bennett et al 2000).
31
It has been demonstrated that patient education and cognitive behavioural therapy as 
well as regular physiotherapy and occupational therapy with minimal medical 
intervention is successful in reducing symptoms of chronic pain syndrome improving 
school attendance (Eccleston et al 2003). Care should be provided in a way, which 
approaches all of the dimensions of the chronic pain and after an initial assessment with 
the child and family, the management plan can be individualised (Perquin et al 2000). 
Non-pharmacological options include, relaxation techniques such as visualisation and 
guided imagery; physical therapies such as transcutaneous electrical stimulation 
(TENS) (Chabal et al 1998), heat and cold therapies are particular useful if there is a 
defined neuropathic element and alternative therapies such as acupuncture, 
aromatherapy and massage are currently being trialled for use in paediatric chronic pain 
as adjuncts to conventional treatments (Rusy and Weisman 2000; Kemper et al 2000; 
van Epps et al 2007).
Drug treatments which are currently used clinically in adult patients with chronic pain, 
include the sodium channel blockers: amitriptyline, the antiepileptics: including 
carbamazepine, lamotrigine and gabapentin (although the precise target of action is still 
unclear) and NMDA antagonists: the most commonly used being ketamine (McQuay et 
al 1995, 1996). Although there have been various randomised controlled trials (RCTs) 
in adult patients which suggest the efficacy of gabapentin in painful neuropathies such 
as in diabetic patients and in post-herpetic neuralgia (Rowbotham et al 1998), there are 
no such trials in paediatric patients with neuropathic pain and in fact there are limited 
case reports only to suggest there may be a use for gabapentin and amitriptyline 
(Wheeler et al 2000; Collins et al 1995).
Most evidence for these therapies is anecdotal in children. Also there are potential 
limitations to the use of these drugs due to the known adverse effects such as 
anticholinergic effects and life threatening cardiac events with amitriptyline (Varley 
2001) and severe hallucinogenic episodes with ketamine.
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Local nerve blocks have been used in children with neuropathic pain and there is some 
evidence for their benefit for complex regional pain syndrome (Lloyd-Thomas and 
Lauder 1995). They are usually used when conventional therapies have failed and are 
beneficial in combination with physiotherapy in a combined rehabilitation setting.
1.8 PAIN IN EPIDERMOLYSIS BULLOSA
1.8.1 Clinical Background
Epidermolysis bullosa (EB) is a genetically inherited skin disorder, characterised by 
extreme fragility of the skin and mucosa and its susceptibility to blister and separate 
from the underlying tissue in response to minimal every day friction and trauma. 
Children with the more severe forms of EB may lead a very disrupted life and may even 
be excluded from daily physical activities or be unable to attend school on a regular 
basis mainly due to the severe pain they are experiencing. Broadly speaking there are 
three main categories, with over 25 sub-types of varying severity depending on the 
affected level within the skin: simplex, junctional and dystrophic, (Fine et al 2000) 
(Table 1-4).
The lesions may be localised or generalised. Each form has a specific cleavage plane 
within the epidermal-dermal basement membrane zone, as well as specific clinical 
manifestations and has distinguishing pathophysiology, mode of inheritance and 
prognosis (Tidman and Garzon 2003).
It is likely to affect 1 in 17,000 live births and it is estimated that there are currently 
5,000 people with the condition in the UK (Dystrophic Epidermolysis Bullosa Research 
Association Research Association-Debra).
Dystrophic EB (DEB) affects 25% of all sufferers and may be dominant or recessive in 
its inheritance. The clinical severity of DEB as well as in all the other major variants of 
EB is based on the type of mutation.
The blisters in DEB usually heal with scarring and are usually associated with some 
degree of nail dystrophy, joint contractures, microstomia, narrowing of the oesophagus 
and pseudodactyly. Those patients with the recessive type may alsol go on to develop 
squamous cell carcinoma.
33
EB Simplex is the most common type of EB and affects around 75% of all patients 
with EB; it is dominantly inherited or may arise as a spontaneous mutation. Currently 
there are approximately seven subtypes of EBS, each with specific clinical 
manifestations. EBS Weber-Cockayne is a variant with blistering confined primarily to 
the palms and soles. EBS Koebner is a different variant with widespread blistering at 
sites of friction.
EBS Dowling-Meara is a form of the disease with neonatal widespread blistering 
progressing to blistering in characteristic clusters. EBS is inherited in an autosomal 
dominant manner but with a few exceptions. The Weber-Cockayne and Koebner 
variants account for the majority of EBS cases.
Junctional epidermolysis bullosa (JEB) is the rarest form of EB with only 5 % of all EB 
patients affected. The usually lethal form of JEB is called JEB-Herlitz. All types of JEB 
are inherited in an autosomal recessive manner.
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Table 1.4: Molecular Classification of EB (Uitto and Pulkkinen 2001)
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1.8.2 Pain in EB: which model exists?
As the bullae may affect both internal and external mucosal surfaces, there is a huge potential 
for both acute and chronic pain in patients with EB. Although there is little research discussing 
the symptom of pain in EB, it was evident from my involvement in the EB multidisciplinary 
teams that pain exists as a major symptom. Many discussions with parents, young people and 
children both at Great Ormond Street and in other centres within the UK, confirmed this. There 
has been one case study relating to the use of amitriptyline, in combination with cognitive 
behavioural therapy, in an 11- year old with junctional EB ( Chiu et al 1999) and there is 
ongoing research at Great Ormond Street investigating the efficacy of amitriptyline in EB in 
neuropathic pain, sleep and mobility ( Howard et al). There have been very few review articles 
providing information on best clinical practice in relation to anaesthesia management in EB 
patients (Herod et al 2002; Iohom and Lyons 2002; Lin and Golianu 2006). I have summarised 
potential sources of pain in EB in Table 1.5.
ACUTE PAIN CHRONIC PAIN
superficial bullae inflammatory pain from scars
corneal ulcers contractural pain
dental dental
gastro-oesophageal reflux osteoporosis
anal fissures constipation
procedural pain
Table 1.5 Possible sources of Acute and Chronic Pain in EB
It is believed as mentioned above that as well as acute and chronic pain, neuropathic pain may 
exist in these patients as anecdotally there appears to be a beneficial response to low dose 
amitryiptyline which is often used as an analgesic for neuropathic pain in adults. The 
pathophysiology behind this proposed neuropathic element to pain in EB may be due to the 
sustained C fibre discharge occurring within the early neonatal period as a result of constant 
painful stimuli which this patient group experiences, inducing “ wind -up phenomenon”- the 
hallmark of central sensitisation. However this needs further investigation.
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Incident pain occurs in EB patients especially secondary to dressing changes, daily activities 
such as bathing and in some cases as a result of any slight movement such as waving “ bye.” 
Control of the symptoms such as constipation and osteoporosis is possible with appropriate 
medication such as laxatives and calcium supplementation, bisphosphonates (Fewtrell et al 
2006) and anti-reflux medication (Fine et al 2008).
Regular dental and opthamological assessments (Wright et al 1994 ; Tong et al 1999) are 
necessary and treatment of superficial skin infections, which seem to exacerbate acute pain, 
with topical or oral antibiotics is essential. Procedures in patients with EB are a major source of 
pain, for example both dressing changes and baths which form a large part of EB management, 
may induce both actual pain due to anticipatory fear.
In some of the children, bathing may be difficult because of the simultaneous exposure of all 
wounds and pain from being lifted in and out of the bath. Due to the physically disfiguring 
nature of EB and the shortened life- span for the patients, psychological anxiety and distress are 
common especially in those with dystrophic EB (Landsown et al 1986). Older children are 
aware that their condition is progressively disabling and they may even lose previously 
mastered skills. They become anxious about school and socialising and this may contribute to 
reduced compliance especially during the adolescent period. Management of dystrophic and 
junctional EB is symptomatic and eventually palliative, as no cure is currently available.
Why I chose patients with EB as the pain model for my research study.
Having now discussed the various types of EB, I would like to explain why I chose this 
patient group to be the pain model for my clinical research. It is evident now that 
neonates bom with a diagnosis of EB, especially those with DEB and JEB will be 
susceptible from birth to a variety of pain sub-types.
Above in (section 1.6.3, Long term effects of neonatal pain, page 26), I have 
summarised the findings both in laboratory and clinical studies, occurring as a result of 
repeated painful noxious injuries, e.g. lower sensory thresholds causing a 
hypersensitivity in the wounded area, delayed facial reaction in response to future pain 
and stronger pain response to future painful stimuli leading to an altered ability to cope 
with stress and pain in adulthood. Particularly in relation to skin wounding and even 
perhaps in the intrauterine period, these patients will have an increase in expression of 
nerve growth factor which in turn leads to hyperinnervation , sprouting of cutaneous 
nerves and therefore hypersensitivity in the surrounding area of skin.
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Consequently the patients may have a combination of not only acute pain but also have 
a susceptibility to chronic persistent pain.
In addition to this, peripheral sensitisation and central sensitisation resulting from 
repetitive and sustained C - fibre discharge is likely to be present, secondary to the 
noxious inflammatory stimuli in patients with EB, therefore leading to possible 
neuropathic pain. In chapter 2 ,1 will explain why this patient group may also have an 
increase expression of peripheral mu opioid receptors enabling the use of peripherally 
applied morphine.
1.8.3 Current pain management strategies used in EB
There are a few reviews providing guidelines for mainly the anaesthetic management in 
EB but there are no studies investigating analgesic management in children and young 
people (Lin and Golianu 2006; Iohom and Lyons 2002).When analgesia is required for 
mild pain e.g. small blisters requiring a quick dressing change, combining simple 
analgesia such as paracetamol with an NSAID e.g. ibuprofen is usually sufficient. 
However with more severe pain associated with dressing changes or baths, opioid 
analgesia and sedation such as midazolam is usually necessary. In this case, doses of 
oral morphine should be in the range of 0.3 -  0.6mg/kg and buccal midazolam, 
0.5mg/kg given around 30 to 45 minutes prior to the procedure (Herod et al 2002). 
Procedural pain has also been managed by novel methods of analgesia such as Entonox 
and fentanyl lozenges (Kalach et al 2002; Schechter et al 1995). In both of these cases, 
the child should be able to self-administer the method of pain control.
In order to manage the chronic background pain administration of long-acting, slow 
release morphine (MST or Zomorph) on a daily basis may be required if milder 
analgesics are insufficient.
One case study has demonstrated the efficacy of amitriptyline (Chiu et al 1999) and 
there is anecdotal evidence from its use on a subset of children and young people with 
EB at Great Ormond Street Hospital, where at low dose, 0.5mg/kg, those with pain 
causing restriction to mobility and sleep interference have benefited further 
strengthening the proposal that there is an neuropathic element. There is currently a 
much larger open labelled trial to further assess its use.
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In the terminal stages of their disease, higher doses of opioid analgesics may be required 
via subcutaneous or intravenous route, in combination with anti-emetics and sedatives 
together in a syringe driver for children.
As well as the above pharmacological therapies, physical and psychological treatments 
such as physiotherapy, hydrotherapy, visualisation and guided imagery should be 
offered, in combination with conventional analgesics, to assist in the management of the 
patient’s pain.
1.9 PAIN ASSESSMENT IN CHILDREN
Accurate pain assessment is essential as it allows pain to be recognised and managed 
promptly. The assessment of pain is a broad term to describe not just the measurement 
of degree of pain but also other dimensions such as the family’s understanding of pain 
and cultural differences. There is a variety of pain assessment approaches in paediatrics 
and their appropriateness of use depends on the age of the child, the child’s cognitive 
awareness, the nature of the underlying pathology and whether the pain is acute or 
chronic.
1.9.1 Pain Assessment tools
Pain perception is individual and children and adolescents vary greatly in their cognitive 
and emotional ability to conceptualise their pain experience. A combination of the uni­
dimensional, multi-dimensional and composite measures, which can identify the 
sensory, psychological and emotional aspects of pain, provide a more accurate and 
realistic estimation. Self -report measures are regarded as the gold standard of pain 
assessment and in order to decide which scale is the best for a particular patient, the 
level of cognitive understanding should initially be determined by the clinician. Table 
1.6 is a guide to the cognitive levels at different ages based on the well - known Piaget’s 
levels of cognitive development. (Piaget 1972).
Pain perception is also based on other factors including, genetic, psychological, socio­
cultural and previous pain experiences (Bursch et al 1998). Children exhibit individual 
reactions to pain e.g. one child may withdraw silently, whilst another may display 
fighting behaviour in an attempt to alleviate pain.
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AGE GROUP COGNITIVE DEVELOPMENT
Infants No verbalisation.
Toddlers Use simple words for pain 
Stranger anxiety -  more distressing if 
parents not present during procedure
Preschool Concrete language to assess pain at
sensory level only
No cause / effect concept
Tries to delay painful procedures
Believe they have pain as a punishment
Magical thinking
School age Fear body mutilation -  more blood = 
greater injury.
Cause / effect understanding 
Understands time 
Logical reasoning -  still related to 
concrete ideas.
Rely less on parents for coping
Adolescents Understand abstract
Need to maintain self esteem
May not display pain behaviour due to
embarrassment / stoical
Lack of compliance with pain treatments
Table 1.6: Understanding of pain perception in relation to cognitive development in 
children based on Paiget’s Theory 1972 ).
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Important factors to consider when choosing a pain assessment tool
Age of child
Cognitive awareness
Acute vs chronic pain assessment
Underlying pathology of pain
Understanding of parents / nurses completing assessment
Length of time of pain assessment -  i.e. daily assessment required then a simple quick 
tool should be used.
Physical ability of child / adolescent completing assessment 
The reliability, validity and discriminatory power of the test.
There are numerous tools presently available to measure infant and paediatric pain, and 
there is no one uniform technique but the various methods can be broadly classified.
• Self -  report
• Physiological
• Behavioural
• Multi-dimensional
1: Self -report measures of pain
Self-report of pain is a description of the child’s subjective experience of pain and does 
not consider the nociceptive aspect of pain. It is regarded as the gold standard 
measurement and several self-report tools have been validated and are reliable methods 
of pain assessment.
There are three factors, which determine which particular tool should be selected:
1) The cognitivedevelopmental maturity of the child
2) The category of the pain; acute vs chronic
3) Whether the pain ratings are required for research or for clinical purposes
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Self -rating scales may be divided into, visual analogue scales, category rating scales 
and numeric rating scales.
Visual Analogue Scales (VAS1
A VAS is a straight line either horizontal or vertical and usually measures 10 
centimetres. A horizontal line has been shown to produce a more uniform distribution of 
scores than a vertical line (Huskisson 1983).
The two end points are no pain and worst pain and the patient is asked to place a mark 
along the line corresponding to their level of pain. The distance in centimetres to this 
mark is used as a numerical pointer of the pain severity.
The main advantage of a VAS is its ease of use and it takes a very short time to 
complete. The results are generally reproducible and it can be applied in a variety of 
clinical settings. It is also sensitive to pharmacological interventions and it has been 
used in children as young as aged 5 (Goodenough et al 1999).
Category Pain Scales
Category or verbal rating scales use words to describe the severity of pain. It was the 
earliest type of pain scale devised and most use the 4 -word category, from none, to 
slight, moderate and then severe. Later pain relief scales were constructed with a 5 - 
point scale ranging from none, to slight, moderate, good and then complete relief. 
Children choose the word, which describe best their pain.
Face scales are the most common form of categorical pain scale used in children, as 
they do not depend greatly on cognitive or language skills (Wong and Baker 1988). 
There are considerable variations of the face scale, ranging from simple line drawings, 
to photographs of children’s faces and cartoon like faces. Some of the scales have 5 
points, some have 6 or even 7. The worst face may or may not have tears and the no 
pain face may be a smiling or a neutral face. There has now been some work validating 
the different face scales (Bieri et al 1990). Face scales are easy to use and are appealing 
to young children and many do possess good psychometric properties (for example 
reliability and validity) (Chambers and Craig 1998).
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Numeric Pain Scales
These are ordinal scales using numbers to measure the increasing degree of pain. They 
are easy to use but the child must understand the concept of numbers. Work on numeric 
scales has shown good correlation between pain diaries and behavioural components of 
pain. It is important to note that the intervals cannot be assumed to be equal, e.g. a 
difference from 2-4 is not necessarily the same change in pain as 4-6. A pain 
thermometer is a variation of the numeric pain scale, graduated from 0 (no hurt) to 
either 10 or 100 (most hurt).These sales have been introduced and developed by Hester 
and colleagues who detected a good correlation between concurrent diary reports of 
pain ( Hester 1979).
Other examples of self -report tools
The Poker Chip Tool allows children to concretely describe their pain using 4 red pieces 
of “hurt” and one white piece of “no hurt”. The validity of this measure is questionable 
and children should have number concept as more red chips equates to more severe pain 
(Hester et al 1990).
The Eland colour scale allows a child to choose different colours of crayons and then to 
devise a key of corresponding pain severity. The child draws the location of the pain on 
a line drawing. This scale however is difficult to validate due to inability to convert the 
drawing into numerical data, but is very useful for those children from different ethnic 
cultures and it also helps to differentiate between separate pains (Eland and Anderson 
1977).
2: Physiological methods of pain assessment
Following a painful stimulus, the metabolic, endocrine and autonomic systems interact 
to initiate the fight, flight and fright response (Anand and Carr 1989). Variables such as 
heart rate (Johnston and Strada 1986), blood pressure (Jay et al 1987) and oxygen 
saturation fluctuate (Williamson and Williamson 1983). These variables are used in 
neonates and infants and those critically ill children who are in the intensive care 
environment, as an objective measure of their acute pain.
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However at present there is no one perfect physiological measure of pain and heart rate 
appears to be the most promising, but by no means is specific (Owens 1986). It is easy 
to record and observe using non-invasive techniques (van Dijk et al 2001).
There are some major reasons why physiological measures should not be used in 
isolation to assess pain, e.g. the variability of the measures is not necessarily related to 
pain, but in fact they reflect an overall response to pain associated with stress and there 
is habituation over time of the physiological indicators to pain, following repeated or 
persistent pain. The physiological responses produced secondary to a noxious stimulus 
reflect the intensity, location and duration of that stimulus but may in fact be 
independent of the final sensation produced by the stimulus. They are not specific and 
may occur for many other reasons including, anxiety, handling, general malaise, for 
example pyrexia.
Consequently they are most useful in acute incident pain, or as an aid to measurement 
of pain in those children who are preverbal or who have an element of cognitive 
impairment. Clinicians usually associate changes ranging from 10- 20 % in the 
physiological parameters, which are measured non-invasively, to a painful experience, 
however there are no validated assessment scores based on these parameter changes. 
During the initial phase of a painful experience the sympathetic nervous system is 
activated producing the changes otherwise known as the fight, flight or fright response. 
It is the measurements of these changes, which provide the most useful information 
related to pain.
However following this acute phase, due to homeostatic mechanisms, the 
parasympathetic nervous system comes in to play, resulting in opposing physiological 
alterations, which do not serve as an aid for pain assessment (Sweet and McGrath 
1998).
3: Observational / Behavioural Pain Scales
These pain rating scales are most often used in the preverbal child or critically ill 
patients, or children undergoing painful procedures in the hospital setting. They may 
also be useful as an adjunct to self-report scales. The behaviours most often related to 
pain include cry, facial expression, posture and rigidity of torso and body movements.
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The following are 4 examples of observational methods of assessing children’s pain:
1) Behaviour rating scales: e.g. the “procedural behaviour rating scale” which was 
originally devised for children aged 6-18 years old, undergoing bone marrow 
aspirations (Jay et al 1987). It is made up of 13 defined behaviours, which are 
suggestive of pain prior during and after bone marrow aspiration. However the scale 
just documents the presence or absence of these behaviours and does not quantify them.
2) It is extremely difficult to assess a neonate’s pain, changes in the facial expression is 
the most consistent pain- related behaviour and the Neonatal Facial Coding System 
comprises of an observational scale based purely on the neonate’s facial response to 
pain including bulging brow, eyes squeezed tightly, open lips, taut tongue etc (Grunau 
and Craig 1987).
3) Premature Infant Pain Profile (PIPP) is a multi-dimensional tool to assess pain in 
preterm infants > 28 weeks and combines both the neonate’s behaviour, as well as 
physiological parameters. It has been validated for use in post-op pain and other non- 
pharmacological procedures in preterm infants (Stevens et al 1996).
4) In older children, the Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS) 
scale has been validated for use in aged 1-7 years post- operatively (McGrath et al
1985). It consists of 6 pain indicators such as crying, facial expression, torso activity, 
which are described in great detail and are scored by the patient’s carer.
Behaviour pain scales are beneficial in the preverbal and post -  operative patient, but 
they have limitations. It is difficult to differentiate between pain related and anxiety 
related behaviour. Also children and adolescents have individualised and inconsistent 
behaviour related to their pain. Some children may exhibit withdrawal of behaviour 
rather than increased expression, in an attempt to achieve their own coping mechanisms. 
It is essential that the observer documenting the behavioural ratings is skilled in pain 
assessment. Therefore behavioural rating scales should be used cautiously, as many 
factors contribute to an alteration in a child’s behaviour.
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1.9.2 Chronic Pain Assessment
Despite the recent advances in children’s pain assessment, there are several populations 
of children where pain assessment is not optimal including children with cognitive 
impairment or neurodevelopmental delay and in chronic pain states (Rucker et al 1996). 
When pain becomes chronic, it influences many aspects of a patient’s life, increasing 
the complexity of the patient’s perception of pain and subsequently the prescribed 
treatment. There are a few comprehensive pain questionnaires, which have been 
designed for use in children with chronic illness and associated pain (Jenson et al 1996):
al The McGill Pain Questionnaire -  originally designed for use in adults, this scale has 
been used with older adolescents and consists of 78 items describing the quality and 
intensity of the pain as well as affective dimensions. These are represented as 20 
clusters of between 3 and 5 similar descriptors ordered for least to most painful. The 
patients circle the clusters, which describe their pain experience.
The questionnaire has 4 subscales; the first and second are the sensory and evaluative 
and measures the intensity and type of pain; the third measures the emotional response 
and the fourth, captures a number of miscellaneous items. It takes approximately 15 
minutes to complete (Melzack 1975).
b) The Vami / Thompson Paediatric Pain questionnaire, has been used to assess chronic 
pain in juvenile rheumatoid arthritis. It takes into account both the child’s and parents 
perception of the child’s pain experience and includes a combination of visual analogue 
scales, colour coded rating scales, and verbal descriptors which provide information 
about the sensory, affective, and evaluative dimensions of children’s chronic pain as 
well as information about the child’s and family’s pain history, symptoms and pain 
relief interventions and socio-environmental situations which influence pain. It contains 
10 pages to be completed each separately by parent, physician and child and may take 
up to 20 minutes to finish (Vami et al 1987).
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c) Douleur Echelle Gustave -  Roussv: DEGR This was developed and validated for its 
use in children aged 2 - 6  yearswith cancer. It is composed of 3 main categories, signs 
of pain, voluntary expressions of pain and psychomotor atonia. This scale requires 
observation for 4 hours and a rating of 17 behavioural items. It is also quite time 
consuming to complete and has not been validated for use on other patient populations 
(Gauvain -  Piquard et al 1987).
d) Pain Diaries Previous work with children who have juvenile rheumatoid arthritis, has 
illustrated the benefits of using a daily pain diary, with a high compliance and indeed 
daily pain measures may be more sensitive than periodic measures, in the assessment of 
subtle, day -  to day changes, which occur following an intervention (Schanberg et al 
1997).
e) The Paediatric Pain Profile (PPP) Children and adolescents who have a 
neurodisability or who are cognitively impaired often have many reasons to be in both 
acute and chronic pain and are unable to easily communicate their pain, e.g. 
medical problems such as hip dislocation, scoliosis and gastro oesophageal reflux 
procedural pain inconsistent signs to suggest pain. This profile is a 20 item rating scale 
specifically for this group of children. It is validated for use in both clinical and 
research situations (Hunt et al 2004).
(f) The Brief Pain Inventory The Brief Pain Inventory This tool was originally devised 
for use in adult patients, who had a diagnosis of cancer and based on The Wisconsin 
Brief Pain Questionnaire (Daut et al 1983 ) where patients with a diagnosis of cancer 
and rheumatoid arthritis were interviewed regarding the differing parameters of pain 
they were experiencing as well as impact of enjoyment of life. The long form BPI was 
then introduced (Cleeland and Ryan 1994).
It provides a quick and easy method of assessing pain intensity as patients note their 
worst, least, average and current pain as well as the impact of their pain on their daily 
function such as sleep, mobility and mood. The BPI has also now been validated for its 
use in those with chronic or a disability related pain (Tan et al 2004). The short form 
only takes 5 minutes to complete.
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1.9.3 What tools I chose for the pain assessment in my research study and why
VAS
I chose the VAS as the tool to measure the pre, during and post dressing changes, as it 
was the quickest for the patients to complete. Many of the children wanted to complete 
the assessments themselves in order to have some control and ownership of part of the 
study and as some had problems with manual dexterity,the completion of the VAS was 
most achievable for them.lt was completed on a daily basis or on the days when 
dressings were changed.
BPI
I chose this assessment in order to have an evaluation of the multidimensional aspects 
of the patients’ pain . I used the short form and focused on the 7 daily functions of 
sleep, mood, mobility, school, friends, general activity, enjoyment of life and 
schoolwork. With permission I modified these slightly in order to be age appropriate. It 
was completed on a weekly basis throughout the study.
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CHAPTER 2: OPIOIDS AND THEIR RECEPTORS
2.1 BACKGROUND
“Among the remedies which it has pleased Almighty God, to give man to relieve his 
sufferings, none is so universal and so efficacious as opium ” (Sydenham, seventeenth century). 
Opium, the dried poppy juice from the unripe seed capsules of the opium poppy contains 
several alkaloids of which only a few; morphine, codeine, noscapine and papaverine are 
clinically useful.
Fig 2.1 The opium poppy (www.opioids.com/images/opiumpoppy)
In the nineteenth century, a German pharmacist, Friedrich Sertumer isolated the 
component of opium with the most marked analgesic activity and named it morphium 
after the Greek god of sleep, Orpheus. Morphine remains the most widely used, even 
though a variety of synthetic opioids have emerged such as pethidine and fentanyl.
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As there is now a more liberal approach to the use of opioid analgesics especially in 
cancer patients, but also in non-malignant pain such as in sickle cell crises (Jacobson et 
al 1997), the total consumption of opioids appears to be increasing worldwide.
Over the last twenty years, considerable progress has been made in the understanding of 
the various endogenous opioid peptides, their anatomical distribution and the receptors 
with which they interact (Nagasaka et al 1996, Harrison et al 1998). In particular, the 
identification of peripheral opioid receptors through which locally applied opioids could 
interact, would provide advantages for paediatric patients, in whom the use of centrally 
administered morphine continues to produce troublesome adverse effects (Stein et al 
1993, Antonijevic et al 1995). Multiple receptor sites, which recognize opioid drugs as 
well as endogenous peptides, exist (Standifer and Pasternak 1997; Satoh and Minami 
1995). The classical subgroups are the mu (p), kappa (k) and delta (5) receptors and 
subsequent activation leads to a variety of effects mediating modulation of nociception, 
locomotion, respiration and motivation .The p receptors have been further sub classified 
into two distinct subtypes, pi and p2 (Pasternak et al 1993).
2.1.1 Location and action of opioid receptors in adult (rat) CNS
All three opioid receptors mu, (MOR), kappa (KOR), delta (DOR), mediate pain 
inhibition and are found throughout the nervous system, in somatic and visceral sensory 
neurons, spinal cord projections and intemeurons, midbrain and cortex (Pasternak 1993; 
Nagasaka et al 1996) (Table 2.1). The actions of OR in the adult CNS will be briefly 
reviewed before focusing on the developmental aspect of OR.
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Table 2.1 Location of opioid receptors in adult (rat) CNS
LOCATION ACTION
Spinal •  Superficial horn o f  spinal •  Presynaptic:
cord hyperpolarisation o f  C
•  Highest density in lamina 1 fibre terminals
and substantia gelatinosa •  Suppress release o f
•  50-70% presynaptic excitatory transmitters
location •  Attenuation o f pain
•  M O R -70% transmission entering
•  KOR & DOR -  30% the spinal cord
•  Postsynaptic: unclear
action
(Dickenson 1994) (Lombard and Beeson 1989)
•  Brainstem, cortex, •  Behavioural and mood
Supraspinal thalamus, amygdala, effects linked with pain
hippocampus •  Endocrine functions
• MOR -  highest in cortex, •  Autonomic reflexes
hypothalamus, raphe, locus •  Role in descending
coerulus mechanism o f  pain
(Atweh and Kumar 1977) (Mansour et al 1995)
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2.1.2 Opioid receptor binding
Opioid receptors are G protein coupled receptors that are activated by opioid peptides 
and alkaloids (Cruciani et al 1993). Both classes of these agonists have analgesic effects 
in the central and peripheral nervous system. G proteins all have a similar structure, with 
an extracellular N terminal region and 7 transcellular domains as well as an intracellular 
C terminal tail structure. G proteins are heterodimers of a, p, and y subunits.
Opioid receptors are coupled with 6 members of the Gi family. Once a ligand has bound 
to the receptor, G proteins can be activated by coupling and GDP is replaced by GTP, 
with dissociation of a  subunit from the py dimer (see Fig 2.2). The GTP a and py unit 
then interact with the effectors producing for example, inhibition of adenylyl cyclase 
which in turn results in diminished pain (Woolf and Salter 2000). GTP then reconverts 
back to GDP and the a unit re-associates with the Py unit. There are potentially many 
steps within this process, as one receptor may activate one or many G proteins, 
conversely several receptors may activate an isolated G protein.
It has been demonstrated that with the application of an opioid agonist, G protein 
activation was significantly enhanced in animal models with peripheral painful 
inflammation, thus providing one possible explanation why topical opioids may be 
effective where peripheral inflammation is present (Zollner et al 2003).
Fig 2.2 Morphine as a G protein coupled receptor showing a p y subunits.
(http://mosberglab.phar.umich.edu/projects/pictures/proj 7pic 1 .gif)
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There are around 20 endogenous peptides, which are mostly derived from three 
precursor proteins: pro-opiomelanocortin (POMC), prepro-enkephalin (PPE) and 
prepro-dynorphin (PPD). Endorphin, enkephalin and dynorphin are the 3 derivatives and 
are relatively selective for the p, 8  and k  opioid receptors respectively.
Opioid binding and subsequent receptor activation to the agonist, initiates a cascade of 
biological events such as analgesia, bradycardia, miosis, sedation, hypothermia and 
depression of flexor reflexes. A series of the following events all resulting in diminished 
pain sensation, occur:
1) Inhibition of adenyl cyclase
2) Activation of potassium conductance
3) Inhibition of calcium conductance
4) Inhibition of transmitter release (Duggan and North 1993, Moises et al 1994)
And more recently, the following observations have extended the actions of opioids to 
include:
1) Activation of protein kinase
2) The release of calcium form extracellular stores
3) The activation of the mitogen activated protein kinase cascade
(Connor and Christie 1999)
2.1.3 Development of the opioid receptors and their function in CNS
The presence and distribution of opioid receptors, the G protein messenger system and 
their endogenous ligands are developmentally regulated (Szucs and Coscia 1990). 
Opioid receptors are present from early fetal life in rat and human in the brain, spinal 
cord and exhibit pre and postnatal maturational change (Kar and Quirion 1995). Studies 
have investigated the development of opioid receptors using tissue homogenate binding 
methods, which provide information relating to the overall receptor density but not to 
the exact localization within the tissue (Attali et al 1990).
However it is difficult to predict from the density of receptor binding sites, the actual 
degree of function of the receptors.
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MOR and KOR binding sites have been found diffusely throughout the spinal cord from 
PO (see chapter 1 page 26, Table 1.3, Age of rat pups and equivalent human age) in 
rat pups, using in vitro autoradiography and selective ligands (Rahman et al 1998). 
Binding peaked at P7 and decreased to mature levels with the MOR binding sites 
becoming denser in the superficial dorsal horn.
DOR binding was initially seen at P7 with no difference seen in the distribution between 
superficial and deeper laminae. The same study, using in vivo electrophysiological 
methods, showed that rat pups at P21 were more sensitive to spinal morphine compared 
to adults and P14 pups even though in PI4, the MOR binding was greater.
The conclusion was that receptor binding sites were not the only factor in determining 
function, but other factors such as coupling of the receptors should also be considered as 
important.
Within the primary afferent neurons, it is now clearly established, with 
immunohistochemistry, using neurofilament antibody (NF200 which stains the large 
non-nociceptive sensory afferents) and MOR and DOR antibody staining of the lumbar 
dorsal root ganglia in neonatal rat pups, that both MOR and DOR are developmentally 
regulated in these afferents during postnatal development.
In fact, they are down-regulated as the neonatal animal progresses throughout 
development, in the large diameter sensory neurons which are the cell bodies of the non­
nociceptive A p proprioceptors and mechanoreceptors (Beland and Fitzgerald 
2001).This results in a more abundant expression of MOR expression in the neonatal rat 
pup in comparison with the adult.
In the neonatal rat, opioids can depress the Ap fibre mediated responses as well as A and 
C nociceptive inputs in contrast to adults, when only the A and C fibre responses are 
selectively depressed. Also, the neonatal withdrawal reflex is known to be mediated via 
the A p fibres (Fitzgerald and Jennings 1999).
Subsequent work using immunohistochemistry on dissociated neurons from cultured 
lumbar dorsal root ganglia in neonatal rat pups has confirmed that there is an over - 
expression of MOR in the neonatal primary sensory afferents. Using calcium imaging, 
these receptors were shown to be functional concluding that this over abundance of 
MOR may be a vital factor in the developmental responses to opioids (Nandi et al 
2004).
54
2.2 PERIPERHAL OPIOID RECEPTORS
2.2.1 Introduction
Opioids are used in both severe acute and chronic pain and provide analgesia via 
activation of their receptors within the CNS. In the nineteenth century Wood first 
reported that morphine induced analgesia occurred when it was applied topically to 
peripheral tissues (Wood 1885). More recently, the presence of peripheral opioid 
receptors in various tissues, which respond to both endogenous and exogenous opioids, 
has enabled effective analgesia without any centrally mediated side effects. As well as 
possessing a potent analgesic role, peripheral opioids are thought to induce an anti­
inflammatory action, which would be an additional benefit for acute and chronic 
inflammatory pain (Stein et al 2001).
2.2.2 Background: Location and possible mechanism of action
Opioid receptors have been detected using immunohistochemisty, simple light 
microscopy and electronmicroscopy techniques, on the peripheral processes of primary 
afferent neurons in laboratory animal studies. Dorsal root ganglia house mRNA for all 3 
opioid receptors and following their synthesis they are transported centrally and 
peripherally via axonal transport (Fig 2.3). They have been located in various tissues 
including lung, colon, immunocytes and skin as well as on sympathetic postganglionic 
neuron terminals (Stein et al 1993). More specifically 29% of MOR and 38 % DOR 
have been located on the unmyelinated cutaneous sensory nerve fibres in adult rat tissue, 
which also express substance P, calcitonin gene related peptide and isolectin B4 
(Coggeshall et al 1997).
The binding properties of both central and peripheral receptors are similar (Hassan et al 
1993). Modulation of calcium currents appears to be the main mechanism of action of 
opioids acting upon peripheral receptors at peripheral sensory terminals. These effects 
are also mediated by the G protein system.
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Also, similar to their action at the soma and central terminals, opioids have the 
following actions at peripheral opioid receptors
1) attenuate the excitability of peripheral nociceptor terminals (Russell et al 1987)
2) attenuate the propagation of action potentials (Andreev et al 1994)
3) reduce the release of excitatory neuropeptides such as substance P 
(Yaksh et al 1980)
4) decrease the vasodilatation, which arises by C fibre stimulation (Stein et al 2001)
Fig 23  The transport of opioid receptors and signalling in primary afferent 
neurons
OP = endogenous OR: EO = exogenous receptor: 
G i/o = inhibitory G proteins 
Sp = substance P
(Stein et al 2003)
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2.2.3 Inflammation, analgesia and peripheral opioid receptors-possible 
mechanisms of action
The action of peripheral opioid receptors is not evident when there is uninjured tissue, 
but under inflammatory conditions the peripheral analgesic effects of exogenous opioids 
are enhanced, most likely due to an up regulation of receptors at the periphery 
(Antonijevic et al 1995).
As the analgesic effects of exogenous opioid agonists are seen as early as 24 hours 
following acute inflammation secondary to a peripheral injection of complete ffeund’s 
adjuvant (CFA) into an adult rat hindpaw, it suggests that opioid receptors are pre­
existent on the peripheral terminals of primary neurons (as CFA normally induces acute 
on chronic inflammation at 12 hours post injection reaching its peak effect at 96 hours). 
It has also been demonstrated that neither the m RNA for mu opioid receptors in the 
DRG, nor the number of peripheral MOR increases in early inflammation, so other 
mechanisms must come into play at the start of the inflammatory process (Stein et al 
1993).
In early inflammation, the tight perineurium, which normally surrounds the peripheral 
nerve fibres, has been shown to be disrupted, facilitating passage of opioids and agonists 
to the receptors (Antonijevic et al 1995). In later stages of inflammation, higher doses of 
OR antagonists have been required at 96 hours in comparison to 12 hours, to diminish 
their effect, suggesting an a probable increase in the axonal transport of the receptors to 
the cutaneous nerve fibres later during the process of inflammation (Zhou et al 1998). 
How does this relate to my laboratory work?
The above work was demonstrated in adult rat models and my study aims to 
demonstrate the presence of peripheral mu opioid receptors in the skin tissue of rat pups 
at various age groups and whether there is developmental regulation and an increase in 
number of receptors following a painful inflammatory insult, quantified by Western Blot 
technique (see chapter 3, page 87).
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2.2.4 Peripheral opioid receptors and immunosuppression
In parallel with the increase of peripheral opioid receptors during inflammation, 
endogenous ligands at opioid receptors are manufactured in circulating immune cells 
and then migrate to the site of tissue injury. During the inflammatory process, memory T 
lymphocytes migrate towards the inflamed tissue and dose dependent release of the {3 
endorphin triggered by inflammatory factors such as corticotropohin -  releasing factor 
(CRF) and interleukin IL-1, as well as environmental stressful stimuli, such as viruses, 
endotoxins and cytokines (Cabot et al 1997).
Migration towards the site of tissue injury is mediated by cell adhesion molecules, 
which are up regulated and located on immune cells and vascular endothelium. The 
opioid peptides also bind to the OR on peripheral sensory nerves inhibiting pain.
This process is abolished if there is immunosuppression, (Machelska and Stein 2002) 
thus enhancing the production of endogenous opioid peptides and promoting the use of 
peripheral opioid receptors in patients who are immunosuppressed would be particularly 
beneficial.
2.2.5 Tolerance at peripheral opioid receptors
There are conflicting reports as to whether there is tolerance at peripheral OR. Studies 
reveal that repeated peripheral administration of opioids in mice produced tolerance, 
which could be reversed using an NMDA antagonist, but there was no initial tissue 
inflammation present (Kolesnikov and Pasternak 1999). There was no tolerance after 
repeated application of loperamide, which is a p agonist in animal thermal inflammatory 
model (Nozaki-Taguchi and Yaksh 1999). Also in two further studies where morphine 
is administered peripherally over time, no tolerance developed (Tokuyama et al 1998; 
Ueda et Inoue 1999). The overall evidence currently is more supporting lack of 
tolerance at peripheral OR.
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2.2.6 Developmental regulation of peripheral opioid receptors
In contrast to the work demonstrating the developmental regulation of opioid receptors 
in the CNS (Beland and Fitzgerald 2001, Nandi et al 2004, Rahman et al 1998, Kar and 
Quirion 1995), there is very little research to investigate the developmental regulation of 
peripheral opioid receptors during an inflammatory process.
There are however a number of developmental processes in neonates, such as the 
perineural membrane maturation, the functional regulation of central nervous system 
opioid receptors and the maturation of the immune system, all of which would suggest 
there might be potential differences in the analgesic and anti-inflammatory actions of 
opioids upon peripheral opioid receptors.
The analgesic effects of peripheral opioids have been tested in infant rats in two studies 
(Barr 1999; Barr 2003).
In the first of these two behavioural studies, peripheral inflammation was induced by the 
intraplantar injection of formalin in p3, plO and p21 ratpups (see chapter 1 page 26, 
table 1.3, Age of rat pups and equivalent human age). Three different doses of 
morphine were also injected into the same area using controls of saline or subcutaneous 
morphine injections. Expression of fos protein in the dorsal horns was measured using 
immunohistochemistry (Barr 1999).
The results showed that, in the P3 pups, local injection of morphine using the middle 
dose was more effective than the same dose given subcutaneously. However the higher 
dose in this age group was equally effective given by both methods probably due to the 
immature permeable blood brain barrier. In the other 2 ages, the intraplantar injections 
of the morphine doses were significantly more effective than the subcutaneous 
injections of the same doses.
The group’s subsequent study explored which of the receptors mediated peripheral 
analgesia. Unexpectedly the kappa agonist was the most effective at local pain reduction 
in both phases of the formalin test in P3 and P21 pups.
Consistent with previous work on opioid receptor development, the 5 agonist was 
inactive in both P3 and P21 most likely due to the later postnatal development of the 8 
opioid receptor (Rahman et al 1998).
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However the p opioid receptor agonist was ineffective at P3 but effective at P21 
contradicting the results of the previous study (Barr et al 2003).
Recent work has concluded that MOR and DOR within the brainstem are 
developmentally regulated (Kivell et al 2004). My following work describes whether 
there is a similar developmental regulation of MOR within cutaneous tissue and if acute 
cutaneous inflammation alters the MOR expression at different ages in the rat.
These preliminary studies investigating the development of peripheral opioid receptors 
in the neonatal rat provide a mechanistic basis for the potential use of low dose locally 
applied opioids in human neonates and older children who experience painful cutaneous 
lesions.
2.3 PHARMACOKINETICS OF MORPHINE THROUGH DEVELOPMENT
2.3.1 Introduction
Although morphine has now been used for many years, there is still a lack of knowledge 
surrounding its pharmacology, both kinetic and dynamic. There are marked 
interindividual differences as well as variability in the kinetics of morphine and its 
metabolites related to age, route of administration, and duration of treatment and 
presence of renal impairment (Chay et al 1992).
In neonates and young children, there is a marked variation between dose requirements 
of opioids and the subsequent response. Many factors contribute one of which is the 
pharmacokinetic handling of opioids (Kart et al 1997). Establishing pharmacokinetic 
differences during development is vital in order to enable dosage guidelines to be 
established for neonates, infants and children. However pharmacokinetic handling is 
only one factor that impacts upon the analgesic efficacy of opioids and age and inter / 
intra patient variability must always be considered. Many pharmacokinetic studies 
involving morphine have been performed in order to evaluate the handling of opioids in 
neonates, infants and children-see below.
Although overall, these studies are helpful in providing a basic understanding, there are 
variabilities in the studies due to design, indication for analgesia, and analytical methods 
(Choonara et al 1989; Bouwmeester et al 2003, 2004).
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The major differences in pharmacokinetic handling at various ages are due to 
differences in clearance and elimination half-life.
2.3.2 Main differences in pharmacokinetic handling of opioids in neonates and 
infants
• Protein binding is decreased in preterm and term infants (18-22%) in comparison 
to adults (20-35%) (Koren et al 1985; Kart et al 1997).
• The elimination half- life of morphine is twice as long in neonates less than 1 
week of age, than in older infants and adults (Kart et al 1997).
• Infants from 2 months of age have similar values to adults (Kart et al 1997; Lynn 
and Slattery 1987) or from 6 months in some studies (Olkkola et al 1995).
• Clearance is similarly decreased in the neonate (McRorie et al 1992; Bhat et al 
1990; Kart et al 1997).
• Immature cytochrome P450 at birth may be a reason for prolonged clearance and 
elimination of some opioids and their derivatives in early life (Hakkola et al
1998). Also the neonate has little CYP2D6 (the most important enzyme substrate 
of the P450 system which is responsible for metabolism of greater than 40 drugs 
including morphine derivatives) and therefore newborns receive little analgesic 
effect from codeine in the first weeks of life (Treluyer et al 1991).
• Possible reduced metabolic capacity to produce morphine glucuronides in 
neonates, although there are conflicting views (Choonara et al 1989; Barrett et al 
1996).
2.4 CLINICAL ACTION OF ORAL AND SYSTEMIC OPIOIDS AND THEIR 
ADVERSE EFFECTS
The clinical use of opioids needs to be titrated against actual pain, as whatever occurs 
whenever opioids are administered to someone in pain is different from when they are 
given to someone who is not in pain. (Table 2.2 shows the various physiological actions 
of opioids and consequent clinical effects).
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For example, respiratory depression, which is seen with the acute use of morphine 
when someone is not in pain, is kept at bay when lower regular doses are given to 
patients with chronic pain (Borgbjerg et al 1996). The main approaches for dealing with 
opiate adverse effects are:
• Reduction of dose
• Specific therapy to treat the side effect
• Opioid rotation
• Change route of administration
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Table 2.2 Actions of opioids
ACTION EFFECT
Depress minute ventilation by 
reducing the sensitivity of the 
respiratory centre to 
hypercarbia / hypoxia
Respiratory depression 
Depress cough reflex
Peripheral vaso / venodilator Hypotension
Inhibits the intestinal smooth 
muscle
Decreases peristalsis 
Increases the tone in pylorus, 
ileo-caecal valve and anal 
sphincter
Stimulation of 
chemorceceptor trigger zone
Nausea, vomiting
Increase tone of detrusor 
muscle
Urinary retention
Triggers release of histamine Pruritus
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Tolerance is the requirement for a higher dose of drug to be administered to achieve 
the same desired pharmacological effect. Patients vary greatly in their ability to 
handle opioids. When the need for a drug escalation arises, a variety of processes 
may be involved.
True pharmacological tolerance is a much less common reason than disease 
progression or increasing psychological distress.
Pharmacological tolerance may be in part caused by the down-regulation, 
internalization and desensitization of opioid receptors, but it is more likely thought 
to be related to mechanisms at the sub-cellular and intracellular level such as in 
regulation of secondary and tertiary messengers e.g. cyclic AMP (Bohn et al 2000). 
Clinically tolerance to the non-analgesic effects of morphine may occur at different 
rates, for example tolerance to respiratory depression occurs rapidly and 
constipation, slowly. Escalating pain in a patient receiving opioids may be due to 
disease progression rather than true tolerance.
Physical dependence is the term used to describe the phenomenon of withdrawal 
when an opioid is abruptly discontinued or if an opioid antagonist is administered. 
Some of the typical signs of a withdrawal syndrome are nervousness, anxiety, hot 
flushes, lacrimation, and sneezing. Gradual weaning to 75% of the previous daily 
opioid dose is recommended and parents and patients should be reassured that 
physical dependence is not synonymous with addiction.
Psychological dependence and addiction refer to a syndrome characterized by a 
constant craving for an opioid mainly to achieve the effects, which are mediated in 
the CNS. It is now known that the risk of developing addictive behaviour secondary 
to the medical use of opioids is low; patients, family and health care professionals 
commonly over estimate the risk of addiction in the clinical setting; physical 
dependence and addiction are often confused and together these concerns contribute 
to some physicians’ reluctance to prescribing opioids (Mortimer and Bartlett 1997).
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2.5 ROUTES OF ADMINISTRATION OF OPIOIDS
The route of administration should be the least invasive and safest route of providing the 
best analgesia
• Oral preparations are best for those patients who can swallow and tolerate them. 
Morphine is available either as liquid or tablets and may be short or sustained 
release preparations. The aim for a child with chronic malignant pain is to 
achieve adequate analgesia with the long acting preparations, which only require 
twice-daily administration. The standard intravenous dose for a child is 0.1 
mg/kg and because only 20-30% of an orally administered opioid reaches the 
circulation, when converting from an oral dose, it should be divided by three 
times. However opioids when given orally, vary substantially with respect to the 
analgesic potency.
• Parenteral administration is used for those patients with impaired swallowing, 
who require rapid onset of analgesia or with gastrointestinal obstruction. 
Continuous infusions of morphine are used for the more acute post-operative 
patients’ analgesia and may be achieved using doses of 0.02-0.03mg/kg in a 
PCA (patient controlled device where a steady background dose of morphine is 
administered with frequent mini doses initiated by the patient. The time intervals 
between boluses (“lock-out period”) are programmed in order to minimize 
overdose. A child as young as 5 may be capable of this method otherwise a NCA 
(nurse controlled analgesia) system is set up (Monitto et al 2000). The 
subcutaneous route is the usual and most appropriate method of administering 
analgesia in combination with sedation, in children who are at the terminal 
stages of their disease and who are unable to tolerate oral medication.
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• Spinally administered opioids.The delivery of low dose opioids near the direct 
site of action at the opioid receptors located in the dorsal horn of the spinal cord 
provide longer spells of analgesia with lower supraspinally mediated adverse 
effects. They are used for post-operative acute pain or in some cases of chronic 
pain. Epidural opioids are effective after thoracic, abdominal and cardiac surgery 
even if given caudally. Facial and segmental pruritus, nausea, urinary retention 
and respiratory depression are the possible adverse effects with epidural 
morphine.
• Transderma 1 fentanyl patches in children are beneficial for those children with 
chronic pain who require steady pain relief and they are thought to have reduced 
side effects especially constipation and nausea (Haazen et al 1999). Fentanyl is 
highly lipophilic and so can be easily absorbed across any membrane. A 
reservoir immediately below the patch in the strateum comeum is established 
over a 12-16 hours once a system is applied and then constant blood fentanyl 
concentrations are maintained for up to 3 days. It is contraindicated for acute 
pain management because of its long onset of action, inability to rapidly adjust 
drug delivery and long elimination half-life and it continues to be released for 
almost 24 hours after the patch is removed (Grond et al 2000). Transdermal 
buprenorphine is a partial opioid antagonist and it has x60 the potency of 
morphine. It needs 24 hours to establish its full effect and this patch can be cut.
• The transmucosal fentanyl lozenge is effective for acute procedural pain. It 
looks like a lozenge and is fruit flavoured. The child rubs the lozenge on the 
inside of the cheek for around 20 minutes when it is rapidly absorbed (around 
25%-33% of a given dose) into the systemic circulation. It lasts around 2 hours 
and has been licensed for use in children as a premedication pre-operation or for 
procedural pain such as in lumbar punctures. It is best used in non - opioid naive 
patients because of the main side effects of nausea and respiratory depression 
(Schechter et al 1995).
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• Intranasal/ buccal opioids are also mucosally absorbed and have been used in 
adults when there is no intravenous access or when they cannot tolerate the oral 
preparation. An RCT in children aged 3-16 years who presented with fractures to 
Accident and Emergency department concluded that the use of intranasal 
diamorphine had a quicker onset than intramuscular morphine, had fewer side 
effects and was a more acceptable method of administration for the patients.
The major side effect of intranasal routes is the localized irritation as seen with 
midazolam (Kendall et al 2001).
• Rectal administration of opioids is a route available for those patients who are 
unable to swallow or have persistent vomiting in spite of anti-emetic therapy. 
The absorption from the rectal mucosa is hugely variable depending on which 
formulation is used as this route may have limited absorption due to partial 
bypassing of the presystemic hepatic metabolism.
• Nebulised opioids have been used in palliative care patients who suffer with 
dyspnoea at the end stages of life (Chandler et al 1999). The mechansim of 
action of inhaled opioids is thought to be targeted at the opioid receptors situated 
in the lung tissue. However this route has low bioavailability of around 5%-30% 
and morphine administered in this way may even cause bronchospasm patients 
with underlying airway disease.
When using different routes of administration or rotating the opioids used, equivalent 
doses will be needed and this needs to be carefully calculated. Unmanageable side 
effects, which are due to opioid action on a particular opioid receptor, will not be 
abolished by switching to a different opioid, which acts upon the same receptor.
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2.5.1 Difficulties with administering opioids via the above routes in children with 
EB
Patients with EB may tolerate oral preparations of morphine, but if they experience 
dysphagia and pain on swallowing due to internal blistering then the morphine may be 
given via a gastrostomy tube. Children with EB are usually unable to use a PCA as they 
have very limited finger dexterity due to fusion of fingers from their scarring and 
contractures. Transdermal fentanyl is contraindicated as children with EB due to their 
extensive skin damage. It has been anecdotally documented that transmucosal fentanyl 
can be rather painful to use in children with EB as it is necessary to rub the lozenge for 
20 minutes on their blistered inner cheeks for any analgesic benefit. The rectal route is 
not ideal for paediatric patients and especially those with EB due the common 
occurrence of rectal blistering preventing any drugs to be administered by this method.
2.6 THE USE OF PERIPHERAL OPIOIDS IN ADULT PATIENTS
2.6.1 Introduction
Historically, opioids have been thought of as having a central action through their 
respective receptors distributed throughout the central nervous system.
However even as long ago as the late 19th century, the English Physician William 
Heberden, included in his renowned Commentaries on the History and Cure of Disease 
(published 1802) that as pain relief for haemmorhoids, he previously advised to apply a 
“mixture o f an ointment and the soft extract o f opium for immediate analgesia” 
(Heberden 1774).
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2.6.2 Peripheral (locally injected) opioids in clinical models of acute inflammatory 
pain
The first controlled clinical trials investigating peripheral (intra-articular) (LA) 
morphine were performed in patients with arthritis and those patients requiring 
knee surgery.
A systematic review was completed in 1997, containing information of 31 RCTs 
with 1500 patients (Kalso et al 1997)). Those reports were included if they 
fulfilled the following criteria:
1) randomised comparisons of I.A. morphine to saline
2) Dose studies of LA morphine
3) IA morphine compared to systemic morphine
4) Use of intra -articular bupivicaine as a marker of internal sensitivity
The Jadad scale was used to assess the validity of the study as a RCT i.e. 
to ensure correct method of randomisation, double blinding and reporting of 
withdrawals. The outcomes of the RCT were whether extra analgesia was required 
or any change in the measures of pain intensity.
The effectiveness of the treatment was defined as a significant difference in pain 
intensity between drug and placebo, covering two periods, up to 6 hours or from 6 
hours to 24 hours; or total consumption of rescue analgesics required.
Only six of the RCTs investigated groups comparing saline, morphine and 
bupivacaine (active control) were valid, but only 4 of these groups demonstrated 
internal sensitivity.
In these 4 studies, LA morphine was significantly analgesic in comparison with 
placebo at both early and late time points, therefore fulfilling the desirable criteria 
set out in 1-4 above. There was no dose response evident in the range of 0.5 mg -  
5mg used in the studies. It was difficult to conclude, due to the low numbers of 
trials assessed, in this systematic review, whether this route of peripheral morphine 
was efficacious.
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However a subsequent systematic review performed by the same authors was 
designed to include the majority of RCTs, aiming to simplify the study sensitivity 
(Kalso et al 2002).
The review included those studies, which fulfilled the criteria as set out 
previously, except 3 time periods were evaluated; 0-2 h, 2-6h and 6-30 hours. 
Sensitivity for each of these time periods was accepted if pain on the VAS was 
30% of 100 in the placebo group. Effectiveness was the difference between the 
quantities of rescue analgesics required via patient controlled anaesthesia, when 
saline or morphine was administered. For any secondary outcomes, effectiveness 
of the RCT was defined as a statistically significant difference in analgesic effect 
between different doses of IA morphine or LA morphine providing a better 
analgesia than systemic morphine.
In this review, 28 RCTs were included and in the early test period, 14 trials were 
sensitive (7 positive), in the intermediate period, 11 trials were sensitive (8 
positive) and in the late period, 12 trials were sensitive (10 positive). 5 mg of LA 
morphine provided the optimum analgesia in any one of the three time periods and 
provided analgesia up to 24 hours, which would be advantageous for the post 
operative arthroscopic day case.
Randomised controlled trials have also assessed the benefit of peripherally injected 
morphine in dental patients and concluded that they were effective where there 
was evidence of local inflammation and in low doses which were ineffective, 
when administered systemically (Likar et al 2001).
2.6.3 Topical opioids in chronic inflammatory pain
Opioids appear to be efficacious if topically applied to areas of local painful 
inflammation. Topical morphine and diamorphine have been researched in adult 
patients suffering from a number of inflammatory skin disorders such as pressure 
sores and fungating lesions (Krajnik and Zylicz 1999). Pressure sores or ulcers 
arise as a direct consequence of prolonged periods of immobilization or secondary 
to an underlying organic condition such as sickle cell disease and diabetes.
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Usual malignancies progressing to such lesions include breast carcinomas, 
squamous cell carcinomas and in children, lymphomas and rhabdomyosarcomas. 
The emergence of such a painful symptom additionally causes psychological 
distress due to altered body image.
The first case reports using topical diamorphine mixed with Intrasite gel was 
reported in 1995 and the 3 patients were all being treated in palliative care units 
(Back et al 1995). Two of the patients in Back’s case reports had pressure sores 
and 1 had a fimgating malignant ulcer. They were already on long acting morphine 
sulphate or intravenous diamorphine as (doses ranging from 240mg -  500 mg in a 
24 hour period) as well as a non- steroidal anti-inflammatory drug. Diamorphine 
10 mg was mixed with the gel and applied to the wounds with a documentable 
effect after the first application, which lasted the duration of 24 hours. Intrasite, is 
a colourless transparent aqueous gel, which contains modified 
carboxymethylcellulose (CMC) polymer together with propylene glycol. It has the 
following beneficial properties:
• creates a mist environment to promote wound healing
• aids debridement
• absorbs exudates at wound surfaces
• the propylene glycol has bacterostatic properties
• generally non-adherent to dressings
The Intrasite /morphine gel mix has shown to be stable for up to 28 days at room 
temperature (Zeppetella et al 2005).
A subsequent isolated case report illustrated analgesia in a palliative patient 
suffering with Hodgkin’s lymphoma, who complained of intractable pain due to an 
inflammatory lesion on her scalp. The patient’s pain interfered markedly with her 
sleep despite large doses of ibuprofen and her altered self -image caused much 
psychological distress. After an application of just 3.2 mg mixed with 4 grams of 
Intrasite gel, to a surface area of 100cm on her scalp, her pain score decreased 
from 7 to 1,2 hours post administration of the gel. The gel as daily applied with 
continuous benefit and without adverse effects (Krajnik and Zylicz 1997).
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Further case series documented an exciting beneficial analgesic effect in the 
majority of patients without any central opioid adverse effects (Twillman et al
1999).In this series of n = 9, patients with painful skin ulceration secondary to a 
variety of diagnoses such as diabetes, Crohn’s disease and fimgating breast 
cancer, documented benefit using this method of analgesia. Morphine infused gel 
(MIG) was made in a uniform manner, so as to contain an equianalgesic dose of 
morphine to constitute a preparation of 0.1% weight to weight solution; i.e. 
approximately 1 mg of morphine mixed with 1 ml of Intrasite gel on a 4 x 4 cm 
gauze dressing.
The earliest time to achieve initial analgesia was 15 minutes. The longest time to 
maintain analgesia was 45 hours but on average the pain free period was 12 hours.
The topical morphine was efficacious in all of the patients except one man, whose 
skin lesion differed from the other patients in that the epidermis was intact and 
there were no definitive signs of inflammation.
This supports the hypotheses from animal studies, that in order for the peripheral 
morphine to provide effective analgesia, there needs to be epidermal and 
consequently perineural membrane disruption, presumably for the peripheral 
opiate receptors to be exposed (Antonijevic et al 1995).
In the above case series, the maximum dose of morphine used for topical 
application was 5mg, which if applied systemically, would be unlikely produce 
such a long-lasting analgesic effect. Apart from the size of the dressing used and 
the % of morphine mixture, there was no matching in the wound type or size or in 
the subject characteristics. What is illustrated in this study, is the variety of 
cutaneous and mucosal lesions which respond to the analgesic effect of peripheral 
morphine / diamorphine.
In a different case series (Krajnik and Zylicz 1999), the morphine gel was used as a 
mouthwash for oral mucositis, a frequent adverse effect secondary to chemotherapy. 
This patient gained almost immediate relief, within 30 minutes of administration. The 
only patient who experienced adverse effects in this report was an elderly woman with 
renal failure and who, after receiving the highest dose of morphine (80 mg) topically in 
this case series, experienced mild constipation.
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Similarly, in this report a variety of doses of morphine and therefore strength of 
morphine gel was administered ranging from 1.6 mg -  80 mg and applied to a range of 
sizes of wounds. The frequency of application differed from patient to patient and the 
length of use and time to documented initial analgesic effect widely varied.
Other examples of such published case reports but each with a slightly different 
emphasis, illustrated the use of diamorphine mixed with an antibiotic gel, metronidazole 
and this combination was used on a female patient whose underlying diagnosis was end- 
stage ovarian carcinoma and associated widespread, necrotic leg ulcers due to her 
immobility (Flock et al 2000).
She was having a combination of analgesics including paracetamol, diclofenac and oral 
morphine in order to attempt to control the resulting severe pain but without success. 
Remarkably, having stopped all analgesics and after one application of topical 
diamorphine / metronidazole gel (0.1%) this patient remained pain-free for 48 hours and 
the opioid toxicity from the oral morphine actually began to subside.
Two case reports of patients with sickle cell disease, who presented with deep 
penetrating leg ulcers not relieved by conventional analgesics, were trialled with topical 
opioids (Balias 2002). In the first patient, an ankle ulcer caused excruciating nocturnal 
pain to a degree of 10/10 on VAS. The woman took up to x 18, 5mg oxycodone tablets 
mainly at night in an attempt to reduce the pain, but without success.
However application of a mixture of her usual debridement ointment, with water and 
one 5mg oxycodone tablet, provided immediate analgesia to such a degree that the 
patient required to take only a maximum of x 2, 5mg oxycodone tablets daily. The 
second patient again had severe chronic bilateral ankle ulceration requiring a variety of 
measures to treat including, 2 hourly pethidine, topical xylocaine gel, grafting, 
debridement, hyperbaric oxygen and growth factor, all of which did not provide healing. 
Again use of the current oral opioid, pethidine, dissolved in water and mixed with 
topical xylocaine gel, produced almost immediate analgesia, reducing the requirement 
for the huge doses of oral opioids consumed.
The above case reports are useful in demonstrating the potential use of new 
pharmacological therapy in patients, but ultimately, randomised case controlled trials 
(RCT) provide the strongest evidence.
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There have been two recent small RCTs, which have been carried out in a similar 
population of adult palliative patients treated in 2 different hospices (Table 2.3, Flock 
2003; Zeppetella et al 2003). One of the groups showed no significant difference 
between placebo and morphine while the other demonstrated the efficacy of topical 
morphine without adverse effects. In Flock’s study, the Intrasite gel acted as the placebo 
and was demonstrated to have no analgesic effects.
Both of the following RCTs comprise very small trial numbers due to a high withdrawal 
rate from the patients. This is typical of such a patient population who are managed in a 
palliative setting as they may deteriorate very quickly.
It may be difficult to obtain an accurate pain intensity measure due to the severity of ill 
health and subsequent inability to complete serial pain scores vital for data analysis.
The majority of palliative care patients will not be opioid naive and this may interfere 
with clarity of results. Also during the study period, symptoms such as the pressure 
ulcers may indeed alter, for example heal or deteriorate both of which may be 
independent or indeed dependent on the actual trial.
2.7 KEY GOAL S FOR USE OF PERIPHERAL OPIOIDS IN PAEDIATRIC 
ACUTE AND CHRONIC INFLAMMATORY PAIN
Neonates, infants and children with acute incident pain and cutaneous inflammatory 
pain such as bums, blistering lesions in EB, mucositis post - operative surgical wounds 
and fungating malignancies such as lymphomas and rhabdomysarcoma have pain which 
may be severe and intractable. Topical application of morphine either as the sole 
analgesic agent or as an adjunct, may provide a life - changing advantage for these 
children, (who are also immunocompromised and therefore possess a minimum 
endogenous opioid response), if proven beneficial. The concept of peripheral analgesia 
with minimal or no systemic adverse effects is an additional beneficial property to this 
novel route of analgesia. The current study is the first to investigate peripheral and 
topical opioid use in paediatric inflammatory pain.
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Table 2.3 Randomised controlled double blind trials
SUBJECTS (Zeppetella et al 2003)
(Flock 2003) ^ 5 recruited and completed
13 recruited 
7 completed METHODS
day 1-3 placebo (Intrasite gel)
day 4-6 drug (diamorphine) or vice versa
wash out period: 2 days
size o f  lesion used: not specified
dose used: 0.1 % weight to weight
Day 1-2 placebo (water in intrasite gel)
Day 3-4 washout
Day 5-6 morphine in intrasite gel or vice 
versa
Dose used: lOmg / ml morphine in 8 g o f  gel 
1 ml o f  water in 8 g o f  gel 
Applied once daily
1 ulcer chosen; average size 8.5 cm2
CURRENT ANALGESIA
Nsaids constant use in both groups; 
Opioid and paracetamol no significant 
difference in use in 2 groups
\
DATA COLLECTED
VAS at 1 and 12 hours post 
application
Daily opioid adverse effect 
profile
N o change in analgesia 
Rescue analgesia permitted 
N o significant difference in 
analgesic use in 2 groups
VAS twice daily am / pm
Daily opioid adverse effect 
profile
No significant difference in two 
groups.
1 patient had opioid toxicity 
beginning in the placebo group 
(Fentanyl had just been increased 
prior to study)
6 patients improved pain 
scores significantly 
compared with placebo at 1 
and 12 hours post 
application. (P < 0.5)
RESULTS
ADVERSE EFFECTS 
/  \
N o systemic opioid adverse 
effects noted 
Less adverse effects with 
morphine group
Average VAS placebo -  
47 mm
Average VAS drug -  
15mm
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CHAPTER 3: LABORATORY STUDY
3.1 BACKGROUND
To understand the actions of peripheral opioids in children, it is important to investigate 
their possible mechanisms and sites of actions. Application of local opioids to the skin 
will lead to activation of opioid receptors in the cutaneous tissue. In Chapter 2 the 
expression of mu opioid receptors in peripheral sensory neurons in the dorsal root 
ganglia and their peripheral terminals and in peripheral tissues such as skin, colon, 
joints and cornea in adult rats, was described ( Stein et al 2003).
Less is known about opioid receptor expression in young rats but expression in dorsal 
root ganglia is known to be postnatally regulated, being more widespread in neonates 
than in older animals (Beland and Fitzgerald 2001; Nandi et al 2004). A greater number 
of cells in the DRG express opioid receptors at birth than later in life (Nandi et al 2004) 
as well as greater binding in the newborn spinal cord (Rahman et al 1998). Expression 
in skin and subcutaneous tissue has not being examined in young animals but it is 
reasonable to hypothesise that this may also be greater than in adults.
In adults, both tissue and sensory neuron opioid receptor expression has been reported 
to be up regulated in the presence of local inflammation (Hassan et al 1993; Coggeshall 
et al 1997; Sengupta et al 1999), and this suggests that peripheral opioids could be more 
effective under these conditions. Quantitative evidence for this is somewhat patchy in 
the literature and it is not known if the above also applies to young animals.
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3.1.1 Aims of study
The aims of the study were to test the following two hypotheses:
1) Mu opioid receptor expression is denser and more widespread in immature cutaneous 
tissue than in adult tissue and is down regulated postnatally.
2) Mu opioid receptor expression in cutaneous tissue (most probably located in the 
sensory neurons that supply this tissue), is up regulated in the presence of inflammation 
in neonatal rat pups
To test these hypotheses, we have used immunohistochemical and Western blot 
analyses of mu opioid receptor expression in both hindpaw skin and dorsal root ganglia 
in normal and peripherally inflamed rats of different postnatal ages. Although there are 
now mouse models for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
(Professor Leena Brucker -  Tuderman, Germany) which are currently being used in 
research to investigate squamous cell carcinoma and a separate mouse model of 
Epidermolysis Bullosa Simplex (EBS) (Professor Dennis Roop, Houston), because the 
primary focus of my work was pain management in children, using peripheral analgesia, 
I wanted to use an animal model, the rat, which is the most commonly investigated 
model worldwide, in the field of neonatal and infant pain research.
3.2 GENERAL METHODS
3.2.1 Animals
All experiments were performed under personal and project licences in accordance 
with the United Kingdom Animal (Scientific Procedures) Act, 1986.
Sprague Dawley rat pups of both sexes were used for this study and were obtained from 
the Biological Services, Central Animal Facility at University College London.
3.2.2 Induction of Inflammation
Inflammation was induced in rat pups aged 3 days (P3), 7 days (P7) and 21 days (P21) 
under brief halothane anaesthetic (2-4 % in oxygen).
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2% carageenan (X. Sigma, St Louis, USA) was 50:50 mixed with sterile water and 
injected intradermally into the plantar surface of the left hindpaw using a 30-gauge 
needle.
The above human equivalent ages are P3, P7, and P21 are 28 weeks gestation, term and 
toddler and above (see table 1.3 page 26, “Age of rat pups and equivalent human age in 
previous chapter”). The volume injected was 5pi for P3 and P7 and 20 pi for the P21 
pups. This dose has been previously used to induce inflammatory pain in neonatal PO­
PS rat pups (Walker et al 2003). In each animal, a single slow injection was 
administered with an aim to spread the carageenan evenly across the subcutaneous 
plantar surface and minimise leakage. These pups were earmarked and on recovery 
from anaesthesia, returned to their dam and litter for four hours with free access to food 
and water. After four hours, the 5 earmarked rat pups were taken from their litter and 
the paw diameter was measured across the midpoint of both hindpaws using a calibrated 
calliper across the dorsal to plantar surface. There were clinical signs of acute 
inflammation i.e. redness and swelling in all of the injected paws. The ratio of the 
injected paw to the contralateral paw was determined in order to standardise for 
variability between animals and changes with growth. The measurements were used to 
demonstrate the presence of acute inflammation.
3.3 PROTOCOL 1: IMMUNOFLUROESCENCE
3.3.1 Preparation of tissue
Pups were administered a lethal dose of sodium Phenobarbital (100 mg/kg, 
intraperitoneal injection). This was followed by a transcardial perfusion with 
heparinised saline (0.9%) and cold (4°C) 4% paraformaldehyde 0.1M in phosphate- 
buffered saline (PBS). The skin from the plantar surface of both the inflamed 
(ipsilateral) and non-inflamed (contralateral) paws along with the dorsal root ganglia, 
(DRG, both ipsi and contra) from the L4 and L5 spinal cord regions were removed from 
each animal. In some cases, the lumbar section of spinal cord was removed as a 
positive control for the MOR antibody. The tissue was post fixed in 4% 
paraformaldehyde for 2 hours and then stored in 30% sucrose in 0.1 M PBS at 4° C.
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Picric acid was also tried as a fixative, as it assists in binding of antigens to their 
respective antibodies, by making the epitopes more accessible. However this method 
seemed to cause abnormal morphology of both the skin and dorsal root ganglia. The 
fixed tissue was mounted in Cryo-M-Bed freezing compound (Bright Instrument, 
Huntington, UK).
Cryostat sections of the plantar surface of the hindpaw skin were cut at 40jim thickness, 
dorsal root ganglia at 10pm thickness (Beland and Fitzgerald 2001) and spinal cord at 
20 pm thicknesses (Raman et al 1998) and mounted serially on gelatinised slides. 100 
pm skin thicknesses have been used in neonatal models of skin wounding (Reynolds et 
al 1997) but having tested various skin thicknesses with MOR and immunostaining, I 
decided to choose 40 pm as the thickness most suitable for the antibody application. 
These slides were air-dried overnight before storage at -20° C.
3.3.2 Establishing an appropriate immunohistochemical method
Immunohistochemistry is a technique to detect, visualise and localise antigens at the 
cellular level, most commonly using primary and secondary antibodies, which bind to 
the antigens embedded in paraffin or frozen tissue sections. A number of different 
methods of immunohistochemistry staining were performed in this study to evaluate 
which technique was the most suitable for both the tissue and antigen being studied.
• Basic immunoflurescence, where a secondary fluorescent antibody binds to the 
primary antibody and detects the epitope of the antigen, was the first approach 
used. However, this technique was not suitable, as a lot of background tissue 
fluorescence was obtained making localisation of the mu opioid receptor hard to 
discriminate. Different concentrations of the mu antibody were tried but with 
similar results each time.
• The diaminobenzidine (DAB) method is another form of 
immunohistochemistry, involving an enzymatic reaction, which assists in 
amplification of the mu opioid receptor antigen signal. The ABC technique is 
then employed to detect the antibody / antigen complex. ABC stands for avidin, 
biotinylated horseradish peroxidase, macromolecular complex, which forms 
complexes for immunoperoxidase staining.
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• This method involves an additional step, using an avidin- biotinylated, 
horseradish peroxidase complex and the final stain is developed, following a 
reaction between a detection kit, which is composed of DAB, hydrogen 
peroxide and nickel.
Avidin is a 68, 000 molecular weight glycoprotein, which has an extremely high 
affinity for the small molecular weight vitamin, biotin and this affinity is actually 
x l,000,000 the binding of most antibodies for antigens and so this process is 
irreversible. Avidin has also 4 binding sites for biotin and most other proteins 
including antibodies can be conjugated with several molecules of biotin. Despite 
the increased sensitivity of this technique over classical immunofluorescence, it is 
better for the sections to be free floating, which means transferring the cut sections 
from the cryostat directly to a container with 0.1M Phosphate Buffer with azide and 
glucose. Any subsequent step in this procedure requires handling the sections with 
a fine paintbrush and with skin; it is very difficult to keep the fragile neonatal tissue 
intact throughout the entire process. This method also failed to detect MOR 
expression in the skin although MOR in the superficial dorsal horns was clearly 
stained.
• TSA Immunofluorescence TSA, Tyramide Signal Amplification. This method 
significantly enhances both chromogenic and fluorescent signals and was found 
to be the most successful method in these studies.
The principles of this method are shown in the diagram overleaf:
80
Fig 3.1 Tvramide Signal Amplification method
Dye Dye Dye
HRPl H jO ?
Dye
DyeDye Dye
HRP
Taken from Molecular 
Invitrogen Detection Tool TSA 
information sheet.
1) The antigen is detected by the primary antibody, followed by a horseradish peroxidase 
labelled secondary antibody in conjunction with a dye-labelled tyramide, resulting in localised 
deposition of the activated derivative.
2) Further dye deposition and therefore higher deposition levels of signal amplification can be 
generated by detecting dye deposited in the first stage with a horseradish peroxidase labelled 
anti-dye antibody in conjunction with a dye-labelled antibody.
Because of the amplification, which occurs, increasing the dilution of the primary antibody by 
just 5 or 10 fold leads to better results.
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This method has been used to detect opioid receptors both MOR and delta (DOR) in 
cultures of brainstem neurons throughout late fetal and early postnatal development 
(Kivell et al 2004). The entire process is rather prolonged and takes up to three or four 
days to complete, however this was the method which worked best for both the skin and 
dorsal root ganglion in this study.
3.3.3 TSA Immunofluorescence protocol for MOR
Once the skin and DRG sections were placed on the gelatinised slide, they were 
blocked in a solution of 5 % normal goat serum and TTBS (0.3% triton X -100 in 
phosphate buffer) and left on the rocker at room temperature for 2 hours. The sections 
were then incubated overnight at 4° C with mu opioid receptor antibody.
The concentration used for the skin sections was 1: 2500 and 1: 40,000 for the DRG's 
and 1: 25000 for the spinal cord (xlO the dilution which was used previously in simple 
immunofluroescence).
The MOR antibody was a rabbit polyclonal antibody raised against the immunogen 
sequence corresponding to residues 1359-1403 of the carboxy terminus of rat MOR (mu 
opioid receptor IgG, Neuromics). The antibody was diluted in 5% goat serum diluted in 
TTBS. The primary antibody was then washed off the slides the following morning 3 
times in 0.1 M phosphate buffer (PB), each wash for 10 minutes, before being incubated 
at room temperature for 90 minutes with biotinylated goat anti-rabbit at a dilution of 1: 
400 in TTBS. The slides were again washed x 3 in 0.1 PB as before and then the 
incubated in Vectastain Elite ABC amplification kit solution for 30 minutes. After a 
further x3 washes in 0.1 PB, the slides were placed in biotinylated tyramide solution 
(Perkin Elmer TSA biotin system) for 7 minutes before a further 3 washes, for 10 
minutes each, as before. Lastly the slides were incubated with FITC avidin 1:600 in 
TTBS and left on the rocker at room temperature for 2 hours covered in foil. After 
washing the slides as before, the slides were cover slipped with gel mount (Sigma) and 
stored in foil at 4°C.
All sections were run concurrently with positive controls (the spinal cord) and 
negative controls (no primary antibody).
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3.3.4 Analysis of immunofluorescent staining
Immunofluorescent slides were examined under a Nikon E800 fluorescence microscope 
through red coloured filter at 470/505nm excitation/emission wavelengths. To estimate 
the intensity of staining, microscope images (xlO, x 20) were captured and analysed 
using MCID (Imaging research, GE Healthcare) image analyser software. For analysing 
MOR immunofluorescence, a threshold was set above background and the area of skin 
with staining intensity above that threshold was measured. The area analysed was a 
rectangle set by the computer programme as 500 x300 pm and fixed for all sections.
The real size of the rectangle was calculated and is documented in all the figures. The 
threshold was also kept constant for all sections and the software measured the number 
of pixels above that threshold in each section. This method is not, therefore a measure 
of staining intensity but a measure of staining above threshold. For this reason it is 
called “relative staining density”. For each skin section, the relative staining density was 
measured in 3 separate regions of epidermal/dermal tissue and the mean intensity 
calculated. The rectangles were placed with one long side on the epidermal surface 
measuring along the section. Measurements were made on both ipsilateral and 
contralateral skin sections; there were 20 sections per animal. The observer was blind to 
whether the sections were ipsilateral or contralateral and the same observer performed 
all the analyses.
The same computer programme was used to analyse DRG immunostaining. For each 
DRG section, thresholds were set and numbers of neurons above the threshold counted. 
Approximately 500 cells per DRG were analysed and the numbers of cells positive for 
MOR immunostaining were expressed as a percentage of the total cell count. This was 
repeated for each of the L4 and L5 DRGs on ipsi and contralateral sides. Again to 
eliminate observer bias, the observer was blind to the experimental status of the animal 
and the same observer performed the analysis throughout.
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3.4 PROTOCOL 2: WESTERN BLOTS
To obtain a more quantitative measure of the total amount of the MOR protein in our 
skin sample, western blots were carried out. In this method, protein bands of a particular 
antigen are obtained by gel electrophoresis.
The protein bands, which are charged ions, run at different speeds depending on their 
molecular weights and can be visualised for quantitative analysis.
3.4.1 Tissue Preparation for Western Blots
The skin of the plantar surface of both feet of P3 and P21 nai've and carageenan 
inflamed rat pups were dissected and snap frozen in liquid nitrogen and stored in 
eppendorfs at -80°C. Fresh tissue is essential for Western Blot analysis and should be 
kept frozen at all times to preserve the protein structure. The skin samples are then 
homogenised in RIPA buffer, which contains proteinases, phosphatase inhibitors in a 
solution of NaCl, NaF, ETDA, NP-40 and Hepes. This homogenises the protein and 
exposes the antigens. The homogenates are then kept on ice for 2 hours and then 
centrifuged (at 4°C, for 15 minutes at 12,000 rpm). The supernatants are then collected 
into sterile eppendorfs.
3.4.2 BCA Assay
The total protein extracted from the tissue was titrated using a BCA kit (Pierce, 
Rockford IL). This is an assay where the protein samples are normalised against a 
known concentration BSA (bovine serum albumin). It is an endpoint reaction, where the 
darker the colour of the samples, the more protein is present. The samples are then 
added to a volume of loading buffer in order to obtain a total concentration of 10 pg of 
protein in lOpl of solution. The normal starting point for a western blot is to load 10 pg 
of total protein per well.
84
3.4.3 SDS-PAGE and Loading of samples for the Western Blot.
All samples were analysed by SDS-PAGE gel (10% Tris -HCL gels, Biorad). 
Appropriate amounts of protein were added to each lane alongside a prestained broad 
range 10,000 -  250,000 kd Kaleidoscope marker (Amersham). They were then 
electophoresed in running buffer (Tris base, SDS, glycine and distilled water) at 100V 
for 90 minutes.
Following activation using methanol and then rehydration, using transfer buffer (Tris 
base, methanol, SDS, glycine and distilled water), a PVDF (polyvinylidene difluoride) 
membrane was then used, onto which the proteins were transferred with 100 V for 45 
minutes.
3.4.4 Immunostaining of Western Transferred Proteins
PVDF membranes were then transferred to blocking agent (5% skimmed milk 
powder in PBS Tween (1ml Tween in phosphate buffer) and left for 1 hour on the 
Rocker. The membranes were then incubated with 1:2500 MOR antibody (Neuromics 
as used for immunofluorescence) diluted in the blocking agent and left overnight on a 
rocker at 4° C. The membranes were then washed 10 times for 5 minutes each in PBS 
with 0.1%Tween and then were incubated with Horse Radish Peroxidase (HRP) -  
conjugated secondary anti-rabbit antibody at 1:2000 for 45 minutes at room 
temperature. The membranes were washed as before.
3.4.5 Development of the protein bands
HRP- labelled proteins were then visualised using an enhanced chemiluminescent 
Substrate (ECL solution Amersham using 50:50 of each reagent) and developed using 
Kodak X- OMAT film in a dark room. The identified bands were labelled against the 
molecular weight of the kaleidoscope marker. The blots were then stripped using 
stripping buffer twice, for 10 minutes each and then washed with PBS tween as before. 
Following blocking as before, the membranes were then reprobed with GAPDH 
antibody at 1: 750 (Chemicon) and left overnight a 4°C.
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The blots were again washed and secondary antimouse antibody was added (1: 2000) 
for 45 minutes, then again washed. They were then developed again in a dark room 
using ECL solution and Kodak film.
It is essential to control for protein levels and this is usually done using GAPDH, as a 
“housekeeping gene”. However anecdotal evidence has suggested that GAPDH is 
developmentally regulated and so an alternative method of controlling for protein levels 
is to use coomassie, a blue dye. The blot is placed in the dye for 5 minutes and then 
destained, using acetic acid. The bands of protein are then clearly visualised as dark 
blue against a lighter background. Using the MCID computer package, the relative 
optical density x the scan area was analysed for the blots and calculated as a percentage
of the GAPDH or Coomassie blue 
values.
Fig 3.2 Summary of Western Blot 
Procedure
1) Proteins o f  interest are loaded into the 
wells are separated by gel electrophoresis, 
usually SDS-PAGE.
2) The proteins are transferred to a sheet o f  
special blotting paper called nitrocellulose, 
though other types o f  paper, or membranes, 
can be used. The proteins retain the same 
pattern o f  separation they had on the gel.
3) The blot is incubated with a generic protein 
(such as milk proteins) to bind to any 
remaining sticky places on the nitrocellulose. 
An antibody is then added to the solution, 
which is able to bind to its specific protein. 
The antibody has an enzyme (e.g. alkaline 
phosphatase or horseradish peroxidase) or dye 
attached to it, which cannot be seen at this 
time.
4) The location o f  the antibody is revealed by 
incubating it with a colourless substrate that 
the attached enzyme converts to a coloured 
product that can be seen and photographed.
5) To control for the amount o f  protein 
loaded, the blot is placed in coomassie blue 
dye and then destained
(Taken from www.bio.davidson.edu/COURSES/genomics/method/Westemblot)
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3.5 RESULTS
3.5.1 The effect of postnatal age on MOR protein levels in plantar skin
Figs 3.3 and 3.4 show Western blots of MOR protein levels in rat plantar skin at two 
postnatal ages, P3 and P21. Two bands are observed, one at 50 kd and one at 70kd.
contra ipsi
Western blot
P3 P21
Coomassie blue dye
contra ipsi
Figs 3.3 and 3.4 Typical Western blots of MOR expression in the plantar skin of P3 
and P21 rat pups. Two bands, 50 kd and 70kd are shown.
87
1= pflSD 
m p2V9D
■  F r a
■  P2V/0
p3/50 p21/50 P3/70P21/70 
n=5gup
Fig 3.5 Mean expression of bands 50 kd (p3/50, p21/50) and 70 kd (p3/70, p 21/70) 
MOR at P7 and P21
(D x a is density of the band x area of band scanned)
The intensity of the two bands from 5 animals in each group is shown in Fig 3.5. A one 
way ANOVA showed that there was a significantly greater expression of 50kd MOR 
protein in the younger P3 animals, compared to P21 (p<0.05). It also showed that there 
was a significantly greater amount of 50 kd MOR protein than 70kd MOR protein in the 
P3 animals (p<0.0001). The 70 kd protein was more variably expressed. Please see 
page 100 for possible explanation and significance of two bands.
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3.5.2 The effect of hindpaw carageenan inflammation on on MOR immunostaining
in plantar skin and DRGs of rat p u p s  P3, P7 and P21
(i) Carageenan inflammation in young rat pups
Carageenan was used as a model of inflammation in the rat pups. Previous reports 
in adults have shown that at four hours strong clinical signs of inflammation are 
evident.
4 - i
■ ■  ipsi 
[= 1  contra
p 3  P 3 in flam e<  p 7  p 7 in flam ed  p21 p21inflam ec
n =5/group
Fig 3.6 Mean (± SEM) paw diameter at P3, 7 and. 21,4  hours post carageenan 
injection. Data is shown for ipsilateral carageenan injected (ipsi) and contralateral 
control (contra) paws. Fig 3.6 shows the clinical signs of acute hindpaw 
inflammation measured as increases in hindpaw diameter in neonatal rats. Using one 
way ANOVA, statistically significant inflammation was evident in the animals of p7 
and p21 (p<0.05) and clinically significant in the youngest pups. This time point 
was therefore used for all the subsequent studies.
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(ii) Immunostaining of MOR in the plantar skin of control and inflamed hindpaws
Contra and ipsilateral images - TSA Immunostain in glabrous skin 
of the hindpaw for MOR in p3 rat pups
Mor -ve
Likely e x p r e s s io n  in 
p e r ip h e ra l  te rm in a ls  o f 
s e n s o r y  n e u ro n s  a s  w ell a s  
in im m u n o c y te s
Animal 1
contra x10 800 x1000 microns
Mor + ve
Ipsi X 1 0  500 x 800 microns
contra x20 450 x 500 microns
Animal 2
Ipsi X 20 300 x 400 microns
(Fig 3.7a)
(Fig 3.7b)
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Fig 3.7a shows examples of typical immunofluorescent staining of MOR in naive 
(contra lateral) and inflamed (ipsilateral, 4 hours post carageenan staining) plantar 
sections in the glabrous skin of the hindpaw in P3 rat pups.
Negative control showed no immunostaining without primary antibody application (fig 
not shown).
Fig 3.7b Positive control of MOR antibody present in the dorsal horn of the spinal cord 
of the control rat pups at all ages using immunofluroescent and DAB staining technique. 
In control tissue, the staining is relatively sparse in the epidermis and dermis but is 
concentrated in large cells in the subcutaneous tissue, which are likely to be 
immunocytes. Future work should then attempt to demonstrate this colocalisaton with 
double- staining immunoflurescence. In contrast, there is abundant staining in the 
inflamed skin, concentrated largely in the dermis while the epidermis remains relatively 
free of MOR expression. Cellular staining is clearly increased but some of the 
cutaneous MOR expression is likely to be on sensory terminals, which are concentrated 
in the dermis. Again this should be the next step using an antibody such as PGP 
9.5.which stains for nerve fibre within the superficial and deep dermis, and around 
adnexal structures such as hair follicles and sebaceous glands. Image analysis was 
performed in 20 contra lateral and 20 ipsilateral sections per animal at P3, in order to 
provide a quantitative analysis of this up regulation.
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n=5/ group
Fig 3.8 The mean relative density MOR immunolabelling in ipsi (inflamed, 4 hours) 
and contra (non-inflamed) plantar skin sections of P3 animals.The mean relative colour 
intensity was established for the contra, 0.07 ± 0.01 (SEM) and ipsilateral 0.11± 0.01 
(SEM) respectively. Although this was not statistically significant; t test 0.08, the trend 
was consistent with visual inspection of sections (Fig 3.8).
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(iii) Immunostaining of MOR in the L4 and L5 dorsal root ganglia of control and 
inflamed hindpaws.
Lumbar DRGs of P7 rat pups immunostained for MOR
:%r
MOR -Ive 
Animal 1
X 20 5 0 0  x 6 5 0  m ic ro n s
MOR -tve
5 0 0  X 6 5 0  m ic ro n s
X 20
Animal 2
5 0 0  x 6 5 0  m ic ro n s
x 10
ipsi contra
Fig 3.9 shows the typical immunofluorescent staining of MOR in non-inflamed (contra 
lateral) and inflamed (ipsilateral) sections of the P7 dorsal root ganglia. Negative 
controls were DRGs without primary antibody resulting in negative immunostaining 
(fig not shown).The DRG sections of the P3 animals were technically difficult to 
section intact and so immunostaining was not successful. The staining is localised to the 
cell bodies in the ganglia although some can be seen in the sensory nerve fibres and 
dorsal roots as well. It can be seen that the intensity of MOR staining is much greater 
on the inflamed side than the contra lateral control side. MOR immunoreactive positive 
cells were counted in 10 sections from each L4/5 DRG and expressed as a % of the 
unstained cells.
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Again the mean values for the relative colour intensity of the contra and ipsilateral 
samples were calculated as 25.2 ±2.1 (SEM) and 15.2± 4.7 (SEM) respectively and a t 
test showed that this difference was very significant with a value of < 0.009 (Fig 3.10)
CONTRA
Fig 3.10 The mean relative density MOR immunolabelling in ipsi (inflamed, 4 hours) and 
contra (non-inflamed) L4 DRG sections of P7 animals.
3.5.3 The effect of hindpaw carageenan inflammation on MOR protein levels in 
plantar skin in rat pups at P3 and P21
(i) Western blot analysis of MOR protein levels in the plantar skin o f control 
and inflamed hind paws
Figs 3.11 & 3.12 show the effect of hindpaw carageenan inflammation upon the 50kd 
and 70 kd MOR protein bands in P3 plantar skin based on the data obtained for Western 
Blot analysis. Fig 3.11 shows that it is the 50kd band that it is significantly up regulated 
in the presence of inflammation, whereas the 70kd band is more variable (Fig. 3-12).
(see pagelOO of this chapter for possible explanations for the two different bands 
detected).
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Although direct comparison cannot be made between Western blots, the up regulation 
at P3 was at least as great as that seen at in P21 animals (Figs 3.13 & 3.14).
1500
k
CD 1000
•  500
contra
ipsi ( carageenan) 
naive
p = 0.003
contra ipsi naive
n = 5 / group
Fig.3.11 Mean expression of 50 kd MOR in non-inflamed (contra), inflamed (ipsi), and 
naive skin 4 hours post carageenan injection in P3 rats. Data based on Western Blot 
Analysis of the sections obtained. Y axis shows the density times the area of band 
scanned as a percentage of GAPDH to control of amount of protein loaded, using the 
MCID image analyser
500-1
contra ipsi naive p = ns
n = 5 I group
Fig 3.12 Mean expression of 70kd MOR in non-inflamed (contra), inflamed (ipsi) and 
naive skin 4 hours post carageenan injection in P3 rats. Data based on Western Blot 
Analysis of sections obtained.
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Y axis shows the density times the area o f band scanned as a percentage of GAPDH to 
control of amount of protein loaded, using the MCID image analyser
2500- tm contra
S  2 0 0 0 - | ■  ipsi
< m  naive
0 1500 
o>
1  1000
2
% 500
contra ipsi naive p ” 0-03
n = 5 / group
Fig 3.13 Mean expression of 50 kd MOR in non-inflamed (contra), inflamed (ipsi), and 
naive skin 4 hours post carageenan injection in P21 rats. Data based on Western Blot 
Analysis of the sections obtained. Y axis shows the density times the area of band 
scanned as a percentage of GAPDH to control of amount o f protein loaded, using the 
MCID image analyser
Io
2000
1500
1000
£ 500
contra
ipsi ( carageenan) 
naive
contra
p= ns
naive
n = 5 1 group
Fig 3.14 Mean expression of 70 kd MOR in non-inflamed (contra), inflamed (ipsi), and 
naive skin 4 hours post carageenan injection in P21rats.
Data based on Western Blot Analysis of sections obtained. Y axis shows the density 
times the area of band scanned as a percentage of GAPDH to control o f amount of 
protein loaded, using the MCID image analyser
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3.6 Discussion
In this chapter I have quantified, for the first time, peripheral MOR expression in 
the skin and its regulation during development and by peripheral inflammation. 
The data presented shows that
• MOR protein levels in the hindpaw plantar skin are significantly up 
regulated in the youngest animal and following carageenan inflammation 
as demonstrated by the Western Blot Analysis. Two bands were visible 
and a significant greater amount of 50kd MOR protein than the 70kd 
protein was present in the P3 animals (see Figs 3.5,3.11 to 3.14)
• MOR expression is up regulated in neonatal plantar skin and significantly 
up regulated in neonatal lumbar DRG four hours post hindpaw 
inflammation as demonstrated by analysis of immunofluorescence 
staining (see Fig 3.7 to 3.10).
The up regulation of peripheral MOR by carageenan inflammation and the 
postnatal regulation of peripheral MOR
As discussed in chapter 2, previous work, using light microscopy has demonstrated that 
MOR is expressed on the fine cutaneous nerves in the inflamed adult paw (Hassan et al 
1993). These studies did not provide much detail and did not say whether the opioid 
receptors were also expressed on normal skin nerves. Subsequent work, using 
immunolabelling combined with electron microscopy to detect the receptors, then 
confirmed that approximately 30% of peripheral cutaneous unmyelinated sensory fibres 
at the dermal -  epidermal junction express either MOR or delta opioid receptors, but it 
was unclear whether these were membrane bound or in structures within the nerves 
(Coggeshall et al 1997). It is generally accepted however, that following peripheral 
inflammation, there is an increase of the intraaxonal transport of opioid receptors from 
the dorsal root ganglia toward the periphery providing an up regulation in the receptors 
at the sensory nerve terminals (Stein et al 1993).
Our first aim was to confirm whether MOR is expressed in cutaneous tissue young rat 
pups and whether postnatal age and effects of carageenan inflammation affected this 
expression.
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Our first aim was to confirm whether MOR is expressed in cutaneous tissue young rat 
pups and whether postnatal age and effects of carageenan inflammation affected this 
expression.
The results of MOR immunostaining in the skin of neonatal rats verify the existence of 
the receptors within the epidermis, but in the absence of electronmicroscopy, it is not 
possible to state the exact location. It is likely however that they are located within the 
peripheral sensory nerve endings as demonstrated previously in adult animal models 
(Stein et al 1990).
Stander et al 2002 has shown immunoreactivity for the isoform of MOR, MOR-1A in 
large fibres in the superficial and deep reticular dermis, in small nerves in the papillary 
dermis, at the dermal-epidermal junction and within the epidermis, using double 
immunofluroescence staining for MOR 1-A and NF (neurofilament) and PGP9.5 
antibodies. This could also be confirmed in neonatal rat tissue as a possible follow-on 
study, by performing double immunofluorescence with a panaxonal antibody such as 
peripherin or PGP 9.5. MOR may also be located on various cells of the circulating 
immune system such as macrophages and lymphocytes (Machelska et al 2002).
Previous work has studied the effects of different inflammatory agents administered to 
neonatal rat pups and has provided useful information, particularly with respect to the 
onset of acute pain and the long term effects of the different inflammatory models.
In this study carageenan was chosen as the inflammatory agent as it acts almost 
immediately at around two to five hours post injection (Walker et al 2003) without 
long-lasting consequences. Although the clinical inflammation it produces may last up 
to 14 days with this agent, there are no alterations in longer term mechanical or heat 
behavioural response, in comparison to CFA( Complete Freunds’ Adjuvant), which may 
produce clinical inflammation lasting into adulthood without resolution.
Formalin has also been shown to be more severe noxious stimuli if injected into the 
neonatal rat pup and may actually lead to sensory neuron death (Tsujino et al 2000).
Up regulation of opioid receptors in the skin was evident on inspection of the 
immunostained sections but image analysis did not reveal significant results.
98
Some reasons to account for this flawed method may be due to the fixation method or 
preparation of the tissue or may be due to the chosen size of the cryostat sections. The 
up regulation was clear, however, on Western blot analysis.
The method used to analysing immunofluorescent staining of opioid receptors in the 
skin is not a precise method, as it defines the colour intensity of the staining and is not a 
quantification of the actual number of cells or structures which are positively stained. It 
provides a relative change in colour intensity and so may not be entirely representative 
of the actual up regulation, which occurred. The method did produce statistically 
significant data for the DRG up regulation perhaps because of the more homogeneous 
nature of the tissue.
Recent work in adults, investigating the mechanism behind the transport of opioid 
receptors to the periphery as well as, how the inflammation at the periphery relays its 
signal towards the DRG, with the following results (Puehler et al 2004):
• There is a biphasic up regulation of mRNA for MOR at an early stage of 1-2 
hours and then at a later stage of 96 hours in the ipsilateral DRG, following 
inflammation, induced by a local injection of CFA in to the hindpaw of adult 
rats.
• There are no significant changes in the mRNA levels for the receptor on the non­
inflamed side.
• At the initial stages of an inflammatory response (1-2 hours), there is an increase 
in opioid binding in the DRG suggesting that the MOR expression may be 
transcriptionally controlled following stages of peripheral inflammation.
• As early as 4 hours post-inflammation, an increase in MOR transport towards 
the periphery occurred, demonstrated in the ligated sciatic nerve.
• Local anaesthetic was shown to block the increase in MOR transcription, which 
suggests that the early up regulation is controlled by neuronal electrical activity.
The above explains that the early up regulation of MOR in the DRG is most likely 
due to increased transcription, presumably triggered by increased spike activity from the 
sensitized sensory nerve endings in the inflamed skin (time scales of the inflammatory 
response differ to that produced in my work, as CFA not carageenan was used in 
Peuhler’s research).
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This is followed by increased transport to the nerve endings in the skin. The above was 
investigated using PCR (polymerase chain reaction technique) which should be 
performed on neonatal tissue as the one of the follow- on studies.
This might explain the less significant results for the immunnoreactivity within the skin, 
which may have been clearer at a later time point. In order to provide a more precise 
quantification of MOR within the skin, western blots were performed.
Developmental regulation of peripheral MOR
The results show that was significantly more peripheral 50kD MOR expression in the 
skin of the P3 pup in comparison to the P21 rat. This is consistent with previous reports 
showing more widespread expression in the infant rat dorsal root ganglion (Beland and 
Fitzgerald 2001; Nandi et al 2004) and greater MOR binding in the infant spinal cord 
(Rahman et al 1998).
The postnatal developmental regulation of key receptors is a common feature of the 
developing nervous system and may well reflect the change from neural communication 
for the purpose of synaptogenesis and growth to mature synaptic transmission and 
modulation of neural signals (Pattinson and Fitzgerald, 2004).
Possible significance of two protein bands
Two visible bands were observed on the Western blot; the 50 and 70 kd bands. 
According to Neuromics, the MOR antibody manufacturer, the 50kd band is the typical 
band, which has been detected in various tissues such as brain, spinal cord and spinal 
cord in the adult rat in previous work (Arvidsson et al 1995). A second less clear band 
was seen at the 70kd in all of the westerns.
Similar banding patterns were reported in a study looking at the expression of MOR in 
the brainstem of rats throughout development. Although there were only 3 animals per 
age group in this study, the 50kd band was more likely to be expressed in the younger 
animal and the 70 kd band in the older animal (Kivell et al 2004). The different 
immunoreactive bands at 50 and 70 kd may be due to the presence of distinct isoforms 
of the receptor.
MOR-1 was first cloned just over 10 years ago and more recently studies have 
identified splice variants of this clone. Evidence now suggests that there are differences 
in the location both intracellularly and regionally of the splice variants.
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For example the MOR-1 or MOR- C are located within the cells of the DRG and spinal 
but not together. Also, MOR-1 is located both pre and postsynaptically and MOR-C is 
located is just located presynaptically (Abbadie et al 2000).
Other reasons to explain the different bands of MOR expression may be post 
translational changes, alternative promoters or splice variant differences. Focusing on 
the 50 kd band, there is a significant increase in expression of peripheral MOR in the 
younger naive neonate as well as following inflammation in both the younger and older 
age animal. A second conclusion is that the 50kd band is more commonly expressed in 
the neonate and the 70 kd band in the older animal.
The next important step would be to determine the exact cellular location of the 
peripheral opioid receptors using a pan neuronal marker such as PGP 9.5and whether 
the peripheral opioid receptors are functional -  this could be analysed using calcium 
imaging.
Clinical Implications
This study had shown that there is an up regulation of peripheral MOR following 
inflammation and that this up regulation is significant in the youngest animal in parallel 
to the findings of Beland and Fitzgerald (2001), in the developmental regulation of 
MOR in neonatal DRGs. It is reasonable to hypothesize; therefore, that the application 
of topical morphine should be more effective when applied to inflamed skin in the 
young rat pups but this would be a potential subsequent study to perform in order to 
confirm or dispute this hypothesis
Clinically, the developmental regulation in the presence of peripheral MOR may have 
implications for the use of topically or peripherally applied opioids in humans. There 
are limitations to extrapolating data from animal studies to man, but the sequence of 
events which occurs in the developing CNS of the rat, has some similarities to that of 
the human; P0 in the rat is approxiamately equivalent to a 24 week premature human 
neonate; P7 to an infant and P21 to an child/adolescent.
The data predicts that opioids will be especially effective when applied topically to 
inflamed tissue as the number of opioid receptors is increased under these conditions.
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The increased opioid expression on sensory nerve endings should lead to better pain 
relief and the increased opioid receptor expression on immunocytes may also relieve 
inflammation. The data also predicts that, since opioid expression is already higher in 
younger subjects, the effect may be even greater in young patients.
Chapter 5 describes the flaws noted in this work and essential follow on studies required 
to enable a clearer understanding of precise location of the MOR receptors as well as 
the specific clinical implications.
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CHAPTER 4: CLINICAL STUDY
4.1 BACKGROUND
My previously published case report (Watterson et al 2004 - see appendix) discusses the 
small pilot study, which was conducted prior to the main research project. It is a small 
case series, which describes the use of topical morphine gel in two teenagers with 
dystrophic EB. The results showed benefit in reduction of acute pain, following the 
morphine application and this benefit continued after prolonged use (five months) in 
one of the cases. There were no adverse effects following the use of the gel in these two 
cases. Following this success, I felt it would be valuable to expand upon the case studies 
with a much larger, randomised controlled study, in order to evaluate further as to 
whether there is reduction of other pain types using EB as the pain model. First I am 
going to briefly discuss the difficulties in conducting essential clinical studies, in 
particular randomised controlled trials in children and young people.
4.2 CONDUCTING CLINICAL TRIALS IN CHILDREN
Clinical practice should be governed by sound evidence and clinical trials in paediatric 
population have led to significant improvements in their health care. However this 
improvement tends to be clustered around certain childhood conditions such as cancer, 
where well organised multi - centre trials based on internationally agreed protocols, 
with strict review processes, have successfully recruited large numbers of patients. 
Conducting research in children is more challenging then in adults for a number of 
reasons related to the small number of patients available for trials in comparison to 
adults. There may also be difficult consent issues, stringent ethical board review 
procedures, lack of incentive for funding, parental anxieties, or even doctors’ 
perceptions that research involves extra work and time for recruitment (Menson et al 
2004). Consequently there is a lack of comparable randomised controlled trials (RCTs) 
in pain research for children and within the Cochrane Central Register of Controlled 
Trials, there are approximately 700 randomised trials of analgesics in children compared 
to well over 5000 such trials in adults (Cochrane Collaboration).
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Unfortunately as a result, clinicians may need to extrapolate results from adult research, 
which is highly inappropriate, especially in the field of pain research, where 
pharmacokinetic and pharmaco-dynamics vary so greatly with age. The risks as well as 
the benefits need to be carefully considered in this group of vulnerable young patients.
It is a well - known phenomenon that there are inclusion benefits for all participants in 
RCTs, the “Hawthorne effect” i.e. people’s behaviour or performance is noted to be 
altered whilst been observed in a situation and this alteration in behaviour is usually 
noted to be an improvement (Adair 1984). This advantage may be volunteer bias, but 
could also be as a result of better monitoring of trial patients.
On a local level, better education for doctors and nurses is required, regarding the 
benefits of trials and the risks of using medications, interventions which have not been 
adequately trialled for use in the paediatric population. Researchers have to consider 
ways of enhancing recruitment of children and young people to trials, such as keeping 
hospital/clinic visits to a minimum and reducing the need for extra blood samples. On a 
more national ( Royal College of Paediatrics and Child Health Guidelines for Good 
Practice 2001) and international level, the EU Medicines for Children legislation has 
ordered for more clinical trials involving paediatric medications to be conducted which 
are age specific, so that there is increased efficacy and safety of medicines used in 
children (Choonara 2000 ; Sammons et al 2004).
4.3 CLINICAL TRIAL DESIGN
I had the opportunity of conducting a RCT which was placebo-controlled, double­
blinded and with crossover design, providing an ideal design for any clinical study.
• Crossover This study used the patients as their own controls therefore avoiding 
difficulties with mismatching. In a crossover trial, the response of intervention A 
is compared to that of intervention B. The major limitation is, whether a 
carryover effect exists between the two treatment periods and to avoid this, a 
wash-out period is necessary and it is essential to test the data for carryover and 
if this exists, then the outcome of the interventions will also be affected 
depending on their sequence (period effect).
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• Placebo-controlled It is a huge benefit to design a trial with placebo control in 
order to minimise bias. This crossover study ensures that each patient however 
not only trials the drug but also the placebo thus removing any ethical risk from 
the research. It has been historically documented that the placebo effect may 
occur in up to 33% of subjects (Beecher 1955). Particularly in studies of pain 
research, functional imaging has detected a placebo response (Petrovic et al 
2002), one mechanism of which is thought to be secondary to release of 
endogenous opioids, as the placebo response may be halted by a naloxone 
injection (Sauro and Greenberg 2005).
4.3.1 Objectives: To investigate the efficacy of peripherally applied (topical) morphine 
in a model of paediatric inflammatory pain using patients with EB.
4.3.2 Design: Randomised, placebo-controlled with crossover design and blinding of 
participants, investigators and assessors. The trial took place over a four-week period 
with, two weeks for placebo application and two weeks for morphine application.
4.3.3 Power calculations and sample size
It is conventional to have a pre-calculated power and sample size prior to commencing 
the study. Any research study relies on the results based on a random sample of the 
population and then inferences are made on the entire population. Power calculations 
are performed to calculate a sample size which may prevent a type I (that is wrongly 
rejecting the null hypothesis) or type II error (that is wrongly accepting the null 
hypothesis). Interim or post hoc calculations may also be performed but are less 
effective. My trial was a multi-phasic randomised controlled trial involving a rare 
condition in a paediatric population and following advice from statisticians it was 
considered not appropriate to calculate power or sample size as the numbers of patients 
who have the disorder even in the entire population are small.
4.3.4 Setting: The study took place at Great Ormond Street Hospital, London and 
within the patients’ homes, throughout the UK.
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4.3.5 Participants
Inclusion criteria:
• Patients in the UK, aged 1 to 18 years, with a diagnosis of dystrophic 
Epidermolysis Bullosa (DEB) were eligible for the trial.
• Patients must have all or part of their routine care at Great Ormond Street 
Hospital EB department.
• Patients should be experiencing either acute or chronic pain at time of 
recruitment as well as having at least 1 area of broken skin (Fig 4.1a shows a 
painful skin lesion in EB and Fig 4.1b shows the extent of skin lesions 
covered with dressings in this young patient with DEB).
Exclusion criteria:
• patients who had a previous adverse reaction to opioids
• those with renal or hepatic insufficiency
• known parental drug misuse.
Fig 4.1 a A painful skin lesion in EB
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1Fig 4.1b Typical dressings required in EB
4.4 RECRUITMENT
The project, including all documentation, received approval by the local research ethical 
committee. A list o f all eligible patients was obtained from the Epidermolysis Bullosa 
patient list held in the dermatology office at Great Ormond Street Hospital. For each 
eligible child, it was then noted when the next inpatient visit had been arranged, so that 
approximately two weeks prior to this scheduled visit, a parental and child information 
leaflet was posted to the family, providing information regarding the study. A covering 
letter addressed personally to the child was also included.
One week after posting the letter, I followed this up with a telephone call with an aim of 
allowing the parent or child to ask any further questions regarding the written study.
At this stage I asked the family to consider participating in the study and if they were 
interested, I would prepare the materials required for the study, prior to their admission 
and would meet them on the ward. If the parents or patients declined to be involved in 
the study, I reassured them that this would have no impact upon their current or future 
management.
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I also attended the EB outpatient clinics within Great Ormond Street Hospital to recruit 
any eligible patients and I also discussed the study details with the EB nurse specialist in 
Scotland and informed her regarding the trial. These patients had joint care with Great 
Ormond Street Hospital and were also all eligible to be involved in the study (See Fig
4.3 for recruitment details).
4.5 CONSENT AND FIRST APPLICATION OF GEL
The first application of the gel took place in hospital or at home in my presence. After 
the parents were fully informed, written consent was obtained according to LREC 
requirements and a general clinical examination took place to ensure the child was well 
enough for participation in the study. The child was asked to choose one particular 
painful skin lesion, which would be used for gel application throughout the study. This 
lesion was measured and photographed. The child was able to continue any regular 
analgesia as well as breakthrough medication and it was asked, that this should be 
documented by the parent throughout the study.
Fig 4.2 Mother applying the gel to a dressing
Fig. 4.3 Participant Flow Through Study
42 EB Patients eligible for trial
1 teenager refused consent
1 parent refused consent
8 other patients either had no suitable 
lesions to use or had no pain at time of 
study
2 already involved in pilot study
30 patients
randomised
No. assigned to placebo first
No. assigned to morphine first
No. who completed the placebo arm 
of the trial second:
No who completed the morphine arm 
of the trial second:
No. who completed the placebo arm of 
the trial first:
Drop-outs 
1 - stinging
No. who completed the morphine arm 
of the trial first:
Drop-outs
1 -  stinging; 1- Admitted to 
hospital
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4.6 RANDOMISATION AND INTERVENTIONS
Participants were randomised to receive two weeks of placebo mixed with Intrasite gel 
and then to receive the drug mixed Intrasite gel for two weeks or vice versa. Each 
patient therefore acted as his or her own control.
Intrasite gel has been used in the management of adult patients with skin wounds (see 
page 72 chapter 2 for its properties). It is a hydrogel composed of water, propylene 
glycol and carboxy methyl cellulose which interestingly are thought to aid absorption 
go drugs from a skin surface which had suffered a bum (Aoyama et al 1984). The chief 
pharmacist randomised each patient using block randomisation method and was the 
only person not blinded in the study.
Block randomisation ensures that balance is enforced within each block randomised 
Therefore as sequential patients are distributed equally to each group, at no time 
imbalance will be large and at certain points, the numbers in each group should be 
equal- i.e. group and periodic balance.
The gel mixture was made up using either morphine sulphate IV preparation 
(10 mg / 2ml) or saline, which acted as the placebo. The pharmacy gave a package for 
each patient which consisted of 2 weeks worth of placebo and 2 weeks worth of drug 
(0.3mg /kg), all identical in appearance and made up in 2ml syringes either labelled 
week land 2 or week 3 and 4. The patient was also given 4 weeks supply of Intrasite 
gel. The agreed overall dose of the morphine mix was 0.3mg / kg for each dressing 
change so the same proportion of the total mix was instructed to be given throughout the 
entire study period. The essential point is that the concentration of the gel mix and the 
dose / kg remained equal throughout the study. The Intrasite gel was squeezed into a 
small gallipot and mixed with either the placebo or drug using a tongue depressor and 
the gel was applied to a chosen painful skin lesion in combination with the patient’s 
usual dressing. The syringes were provided to the parent in a locked box and asked to be 
kept in the fridge. Sufficient quantities of tongue depressors as well as gallipots were 
also provided.
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4.7 OUTCOMES AND DATA COLLECTION
4.7.1 Predefined primary outcomes
The primary outcomes were pain levels prior to, throughout dressing changes and one 
hour post dressing change.
• The pre dressing change pain scores were used to define background pain 
throughout the study period as the earliest time following a dressing change to 
the next pre pain score was 24 hours.
• The pain during the dressing changes was used to quantify procedural or 
incident pain.
• The post dressing change pain score (1 hour post) were used to define post­
procedural pain through the study period.
•
4.7.2 Predefined secondary outcomes
The secondary outcomes were appearance of the skin lesion through the 4 week period 
as well as quality of life. An adverse effect profile was also recorded.
4.7.3 Data collection
Following consent, a patient history sheet was completed, which included demographic 
details as well as current analgesia, current symptoms associated with EB, any skin 
current infections. On a body outline diagram (see appendix), the skin lesion was 
documented with its dimensions. The patient was then shown their diary, which had 
written instructions regarding the making up of the gel mixture, and the researcher’s 
contact details.
The patient or parent were asked to complete pain diary sheets (see appendix), which 
consisted of visual analogue scales pre, during and 1 hour post dressing change as well 
as documenting any skin infections, or incidents which could exacerbate pain such as a 
fall. Any emergence of adverse effects possibly related to the opioids such as nausea, 
vomiting, constipation were also documented on a daily basis and given a score out of 
10 if present (10 = worst).
On a weekly basis the parent was asked to comment and document whether the lesion 
looked worse, the same or better than at the start of the study and using an amended 
(with permission) version of the Brief Pain Inventory (Cleland-see appendix).
I l l
Aspects of quality of life were documented such as schoolwork, relationships, and 
sleep. As the lead researcher, I recruited all the patients and followed up with weekly 
phone calls to ensure that there were no parental concerns and also to remind parents to 
complete all the diary sheets. In the majority of patients I made a home visit half way 
through the study, to encourage both the child and parent to complete the trial, as well 
as to document any extra, relevant information. The children lived throughout Great 
Britain including Wales, Scotland and Ireland. I gave the family a stamped addressed 
large envelope to return all the diary sheets after completion of the study.
4.7.4 Statistical Analysis
Due to the complex nature of this multi-phasic trial with composite outcomes, the 
statistical analysis was discussed and advice given by the statistics team, led by 
Professor Tony Cole, at the Institute of Child Health.
Each study day comprised of three assessment sessions:
1) Pre application of either morphine/placebo
2) During application of morphine/placebo
3) Post application of morphine/placebo
As the study was a crossover design, it was first essential to perform significance testing 
on the following:
• Carry-over effect
• Treatment effect
• Period effect (i.e. is there a change over time irrespective of treatment?)
(Jones and Kenward 1989)
The significance tests chosen to perform theses analyses were two - tailed paired t tests 
and were performed for the background, incident pain and post-procedural pain scores.
I also analysed separately, the pain reduction of the pre application scores (background 
pain) from the first baseline pain scores using paired t tests, and compared the results of 
those who had daily dressings with those who had less frequent dressings.
Period 1 is week 2 and period 2 is week 4. Two way ANOVA with post hoc Bonferroni 
test were also performed to analyse the confounding variables of size of lesion and age 
of child on the pain scores. Both Excel XP and Prism 3.0 were used to perform 
statistical analyses.
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4.8 RESULTS (Fig 4-2 Participant flow chart)
At the time of the trial, out of 42 children at Great Ormond Street with DEB, there were 
a possible 42 patients who could have potentially been recruited for the trial. However, 
at time of recruitment, 8 of these children did not have appropriate lesions or did not 
complain of pain. 2 of the teenagers had already participated in the pilot study and so 
were not eligible. Only 1 teenager and 1 parent did not give consent for the trial. The 
parent who refused consent had a child who was just lyear old and felt frightened about 
enrolling their son at such a young age. The teenager gave no particular reason for not 
consenting.
A total of n=30 patients were enrolled. A total of six assents were given by young 
people aged 12-18.
Of these 30, 2 of those patients randomised to morphine for weeks 1 and 2, did not 
complete the study as 1 patient was admitted to hospital because of an intercurrent 
illness and 1 complained of stinging from the gel on day 1 so no data was collected. 1 
patient who was initially randomised to saline for weeks 1 and 2 did not complete due 
to stinging form the gel, again without any collected data.
Of the remaining 27 participants, a total of 24 completed data sheets were returned and 
analysed for the study. Fifty per cent of the subjects were female and fifty per cent male. 
Table 4.1 shows the patients data for age, weight and the variation of surface areas of 
lesions used in the trial. Fig 4.4 displays how frequently the dressings were changed in 
the patients and Fig 4.5 shows which analgesics, either singly or in combination were 
taken by the patients prior to and throughout the study
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A G E 1.74 16.95 9.28 9.19
(yrs)
WEIGHT 12 70 26.7 25.5
(kg)
SURFACE 18 1320 231.77 102”
AREA OF
LESION
(cm2)
Table 4.1 Patient Characteristics n =30
Frequency of dressing  
change
□daily
■ alternate days
□ 3/week
□ twice /week
Fig 4.4 Frequency of dressings
Analgesics taken prior to trial
□ paracetamol
■ NSAIDS
□ codeine
□ opioids
■ amitriptyline
□ gabapentin
no. of patients
analgesia
Fig 4.5 The number of patients who were prescribed a variety of analgesics prior to and 
throughout the study. Some patients consumed more than one type o f pain relief 
medication.
4.8.1 Crossover analysis The following three tables, Tables 4.2 to 4.4 provide the data 
for the crossover analysis of the background pain, incident pain and post 
procedural pain. Following each table, I have calculated and concluded whether 
there is a carry-over, treatment, or period effect based on Jones and Kenward 
definitions in Design and Analysis of Crossover Trials (1989) as recommended 
by the Institute of Child Health of London Statistics Department.
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Table 4.2 Background pain (Values tabulated = VAS (mm / 100) day 8/22, 24 hours 
post first application of morphine / placebo). Data for 1A IB 1C and explanation see 
next page
Patient
no.
GROUP 1
A morphine 
(period 1)
B placebo 
(period2)
1 6 3
2 0 27
3 7 29
4 3 5
5 0 0
6 29 10
7 5 11
8 6 9
9 0 0
10 9 63
11 0 15
12 0 0
13 27 14
GROUP 2
B placebo 
(Period 1)
A morphine 
(Period 2)
14 0 0
15 14 4
16 0 0
17 79 47
18 84 56
19 43 1
20 16 10
21 9 0
22 60 27
23 6 8
24 3 20
25 15 0
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1A) Carry over effect
The null hypothesis being tested is that the carry over effects are equal between groups 
one (A = morphine first) and groups two (B = placebo first). This is tested, by 
comparing the sum of the values over both treatment periods between groups 1 and 2.
A 2-sample t test yields a p value of 0.18 and the conclusion is that the carry over effect 
is not significant.
IB) Treatment effect
We can only test this if the carry over effects are equal or not significant. The null 
hypothesis here being tested is that the treatment effects are equal. This is tested by 
comparing the difference, between period 1 and period 2 for the 2 groups. For group 1 
this will be time spent on treatment A minus those after spent on treatment B. For group 
2, differences will be for after time spent on time B minus those, after time spent on 
treatment A.
A 2-sample t test of the differences yields a p value of 0.0113.
The outcome of the 2-sample t test gives a 95% confidence interval for the difference - 
20.46 of (-35.83, - 0.5093). To estimate the size of the treatment effect, we take half of 
the difference between the average differences for each group and hence a 95% 
confidence interval for this would be -10.23 (-17.41, - 0.254). Thus it can be 
concluded that morphine has a significantly better effect on background pain 
reduction than placebo.
IC) Period effect
It is of interest to formally test the period effect; i.e. is there a change over time 
irrespective of treatment. This is performed by testing the difference between treatment 
A and B for the two groups.
For group 1 the differences will be for after time period 1 minus those after time period 
2; for group 2, differences will be for after period 2 minus those after period 1.
A 2-sample t test of the difference yields a p value of 0.46. The 95% confidence 
interval for the estimated period effect of 2.25 is (- 4, 10.45). This shows that there is 
not a significant period effect.
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Summary of crossover analysis for background pain
Following the crossover analysis, there was a significant treatment effect with morphine 
on pain reduction of background pain, without carryover or period effect (p= 0.0110). 
There is no such significant treatment effect with placebo.
It is clear from Fig 4.6 that topically applied morphine gel provides significant pain 
reduction over at least a 24 hour period. This is not true of pain reduction with placebo. 
However the reduction is only significant when the dressings are changed daily (Fig 
4.8; p<0.02) and although there is a clinical improvement in pain for those children who 
have less frequent than daily dressings, this was not a significant result (Fig 4.7). This 
group of children may need higher doses /kg of morphine applied to achieve a 
significant pain reduction but further dosing studies should be performed to decide this. 
The age of the child or the skin lesion size does not effect the background pain 
reduction (Figs. 4.9& 4.10).
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Table 4.3 Incident / Procedural pain (Values tabulated = Mean of total VAS (mm /100)
week 2 /4
during dressing change).Data for 2A 2B 2C and explanation next page
Patient
no.
GROUP1
A morphine 
(period 1)
B placebo 
(period2)
1 59 39
2 28 14
3 19 16
4 4 5
5 36 16
6 20 10
7 60 77
8 77 60
9 0 0
10 68 83
11 27 19
12 35 0
13 42 31
GROUP2
B placebo 
(period 1)
A morphine 
(period2)
14 4 3
15 17 8
16 9 50
17 34 37
18 75 62
19 81 1
20 32 34
21 100 94
22 21 87
23 51.5 61
24 90 89
25 58 5
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2A) Carry over effect
A 2-sample t test yields a p value of 0.228 concluding that the carry over effects are not 
significantly different.
2B) Treatment effect
A 2-sample t test yields a p value of 0.655 showing that the treatment effect is not 
statistically significantly different between morphine and placebo for procedural pain
2C) Period effect
A 2-sample t test gives a p value of 0.305 revealing that there is no significant period 
effect
Summary of crossover analysis for incident pain
The crossover analysis demonstrates that there is no significant treatment, 
carryover or period effect with reduction of incident pain with either morphine or 
placebo. Children with EB have severe pain at the moment the dressing is removed and 
anecdotal evidence suggests that, even higher doses of oral opioids do not reduce this 
pain. This may be due to a combination of the immense anticipatory fear as well as the 
pain and sedation is often more beneficial in combination with an opioid in this 
situation. Again the size o f the skin lesion and age of child do not affect the above 
results (Figs 4.11, 4.12).
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Table 4.4 Post procedural pain Values = mean VAS (mm /100) week 2 / 4, 1 hour 
post dressing change. Data for 3A 3B 3C see explanation next page
Patient no. GROUP 1
A morphine 
(period 1)
B placebo 
(period2)
1 7 0
2 0 0
3 0 0
4 4 5
5 1 0
6 0 0
7 9 16
8 6 4
9 0 0
10 6 3
11 9
12 14 0
13 25 13
GROUP2
B placebo 
( period 1)
A morphine 
(period2)
14 0 0
15 10 3
16 0 6
17 36 23
18 15 18
19 2 0
20 14 10
21 6 3
22 50 70
23 8 9
24 3 1
25 0 0
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3A) Carryover effect
A t test yields a p value of 0.175 concluding that the carry over effect for post 
procedural pain is not significant
3B) Treatment effect
A t test gives a p value of 0.64 showing that there is no significant treatment effect 
3C) Period effect
A two-sample t test yields a p value of 0.0216, with an estimated size of this effect, 
giving a 95% confidence interval of 3.13 of (0.49, 5.6).Thus there is a statistically 
significant effect of whether morphine or placebo is given first or second for post 
procedural pain.
Summary of crossover analysis for post procedural pain
The crossover analysis demonstrates that there is no significant treatment, carryover or 
period effect with reduction of post procedural pain with either morphine or placebo and 
again the age of the child and the size of the skin do not affect the above results (figs 
4.15 and 4.16). However analysing all the patients’ pain scores together for both day 
8/22 and the mean scores for period 1 and period 2, both morphine and placebo 
significantly reduced post procedural pain one hour after dressing change (figs 4.13, 
4.14)
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4.8.2 Overall background pain reduction from baseline pain on first application of
morphine and in relation size of lesion and age of patient
Fig 4.6 is the data of all children analysed together but the data from those children who 
had daily dressings was also analysed separately from those who had less frequent 
dressings as it is not appropriate to compare one pre value after 24 hour application of 
gel (daily dressings) with a child who may have had a dressing 72 hours previously (less 
frequent dressings) (Figs 4.7 & 4.8).
The mean pre scores of period 1 (week2) and period 2 (week4) were analysed in 
relation to size of lesion and age of child, to investigate whether these were both 
potential confounding variables (Figs 4.9 & 4.10).
■ baseline pain
□ first pre morphine
■ first pre placebo
n = 24
PO.Ol
Fig. 4.6 VAS scores with morphine and saline (placebo) at day 8 and day 22 (depending 
on randomisation order).The data was analysed using paired T test showing that there is 
a significant difference in baseline pain reduction with morphine, p< 0.01 with a mean 
VAS of 11.96 ±3.7 (SEM), compared to a mean VAS of 19.08 ±5.12 (SEM) with 
placebo.
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□  morphine 
■ I placebo
p-ns
n=11
Fig. 4.7: Percentage reduction in VAS from baseline pain at day 8 and day 22 
(depending on randomisation order) in those who had less frequent than daily 
dressings. The results were analysed using a paired t test; the mean reduction with 
morphine is 42.27±12.5 (SEM) and with placebo is 19.53±11.5 (SEM). Although there 
is a clinically a greater pain reduction with morphine, it is not statistically significant.
□  morphine 
■  placebo
p <0.02
n= 13
Fig. 4.8: Percentage reduction in VAS from baseline pain at day 8 and day 22 
(depending on randomisation order in those who had daily dressings. The results were 
analysed using a paired T test and the mean reduction with morphine was 51.8±12.9 
(SEM), compared to mean reduction o f 29.69± 10.57(SEM) with placebo.
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Fig 4.9 : The mean reduction in VAS from baseline pain to the mean pre pain scores 
during period 1 and 2, with morphine and placebo in relation to size o f lesion. The 
results were analysed using a two way ANOVA and were not statistically significant.
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Fig 4.10: The mean reduction of VAS from baseline to the mean pre pain scores during 
period 1 and 2, with morphine and placebo in relation to age of patient. The results were 
analysed using a two way ANOVA and were not statistically significant.
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4.83 Overall incident pain reduction in relation to size of lesion and age of patient
80 - m orphine
p lace b o
I
0-250 250-500 500-750
size of lesion 
(cm2 )
p =ns
750+
□
n=24
Figs 4.11 Mean reduction in VAS during a dressing change during period 1 and period 
2 and in relation to size. The results were analysed using two way ANOVA and were 
not statistically significant.
morphine 
placebo
o ^  
5  £
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10-15 15-20
age
(years)
n=24
Fig 4.12 Mean reduction in VAS during a dressing change during period 1 and period 2 
and in relation to age.
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4.8.4 Post procedural pain reduction 1 hour after first application of morphine and
in relation to size of lesion and age of patient
The pain reduction from pain during the dressing changes to pain at 1 hour post 
dressings was analysed. The data from all the children regardless o f the frequency of 
dressings was analysed together and were results of both day 8/22 ( depending in 
randomisation order) as well as the means of period 1 and period 2 are illustrated (figs 
4.13 & 4.14).
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X
CUD m orphine during 
CUD morphine pos t  
■ 1  p lacebo during 
■ ■  p lacebo post
p<0.0001
n=24
Fig 4.13 Mean VAS during and 1 hour post dressings on day 8/22. The results were 
analysed using one way ANOVA; the mean VAS during a dressing change was 
42.46±7.3(SEM), 1 hour post dressing the mean VAS with morphine 
wasl0.25±3.5(SEM). The mean VAS during dressings with placebo was 42.5±7.0 
(SEM) and 1 hour post dressings; the mean VAS with placebo was 10.29±3.47 (SEM). 
The mean VAS reduction 1 hour post dressing change was statistically significant 
(PO.OOOl) with morphine and placebo.
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■ m orphine during
▲ m orph ine p o s t
■ p laceb o  during
a p laceb o  p o s t
p<0.0001
n=24
Fig 4.14 The mean VAS scores over periods 1 and 2, 1 hour post dressings. The mean 
VAS during dressings with morphine was 37.7± 6.1 (SEM) and 1 hour post dressings the 
mean VAS with morphine were 8.2±2.9 (SEM). The mean VAS during a dressing was 
39.9±6.3 (SEM) with placebo and 1 hour post dressing was 8.6±2.6 (SEM). The results 
were analysed with one way ANOVA and mean VAS reduction was statistically 
significant with morphine and placebo 1 hour post dressing change ( p<0.0001).
1  E 
c E
re ■ 
©
IOU-1
100 -
5 0 -
A A
A
A
A
aA a
128
a
i !
CD '
0-250 250-500 500-750
size 
(cm2)
750+
m  morphine 
■■ placebo
p-ns
n=24
s i®
10-15
a g e
(y e a r s )
11=24
15-20
m o r p h in e
p l a c e b o
p -n s
Figs 4.15 & 4.16 Mean VAS post dressing change in relation to size of lesion and age 
o f patient during periods 1 and 2. The results were analysed using two way ANOVA 
and are not statistically significant.
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Fig 4.17 BPI outcome scores. There was no statistically significant difference between 
morphine and placebo in the BPI outcome scores. Using the mean scores documented 
on a weekly basis, there was no statistically significant difference detected with 
morphine or placebo in any of the criteria, which represented for the purpose o f this 
study, an overall quality of life score. Generally in patients with EB, a variety o f issues 
such as body image, self -  esteem, mobility have a huge impact on their quality of life 
and not just their pain (Fine et al 2004).
The subjects’ 21 parents were also asked to comment on the appearance of the skin 
lesion on a weekly basis and document this as worse, same or better. If the morphine 
was applied for the first two weeks, the skin appearance with morphine was comparable 
with the placebo throughout. The morphine may have provided some initial healing of 
the lesion which continued throughout the placebo arm. If the patient was randomised in 
receiving placebo first, there was a much better improvement on skin appearance with 
morphine in weeks 3 &4 than with placebo in the first two weeks. Morphine is known 
to have anti-inflammatory properties and the application of peripheral opioids directly 
to the peripheral opioid receptors may induce skin healing which would be a great 
additional benefit for EB patients.
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Fig 4.19 Possible opioid adverse effects
This shows the adverse effects graded out o f 10, noted with placebo and morphine 
mixed with Intrasite gel. The most severe effect was itch, followed by drowsiness with 
both saline and morphine. These 2 symptoms are extremely common problems 
experienced by patients with EB and may not be to the topical opioid.
The differences in effects with placebo and morphine were not significant. 54% of the 
subjects scored 0/10 in relation to at least any of the three adverse effects asked to be 
recorded. The most frequent side effects noted were itch and to a lesser extent 
drowsiness; there was no significance difference with the placebo or morphine gel, 
which would firmly suggest that these symptoms were in no way related to the study. 
Itch is a very common symptom in EB as well as drowsiness secondary to anaemia, 
poor nutritional status and immunodeficiency. The relative low number of side effects 
suggests that the topical morphine is not systemically absorbed in sufficient quantities.
131
4.9 SUMMARY OF RESULTS
The following are a summary of the results.
• There was a significant treatment effect with topical morphine on pain 
reduction of background pain, without carryover or period effect (p=0.0110). 
There is no such significant treatment effect with placebo.
• Topically applied morphine gel provides significant pain reduction over at least 
a 24-hour period. This is not true of pain reduction with placebo. However the 
reduction is only significant when the dressings are changed daily and although 
there is a clinical improvement in pain for those children who have less frequent 
than daily dressings, this was not a significant result. This group of children 
may need higher doses /kg of morphine applied to achieve a significant pain 
reduction but further dosing studies should be performed to decide this.
• Incident pain is not significantly reduced with topical morphine, which is not a
surprising result as it is evident that a dressing change is an acutely painful 
procedure
• Post procedural pain is significantly reduced by both placebo and morphine but 
this is most likely due to the fact that the acute pain from the dressing change is 
over and the patient experiences no significant relief at this time point with the 
morphine gel.
• There appears to be a consistent pain reduction with placebo and this required 
further exploration. Intrasite gel may in fact have healing and therefore pain 
relieving properties and this should be studied.
• The age of the child or the skin lesion size does not significantly affect the 
background/incident or post procedural pain reduction.
• Using the BPI, quality of life is not significantly improved by use of topical 
morphine
• The appearance of the skin lesion under the topical morphine is not enhanced 
by either topical morphine or placebo
• Itch and drowsiness were noted as the most common side effects experienced, 
but there were no significant differences between topical morphine and placebo
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4.10 CONCLUDING REMARKS TO CLINICAL TRIAL
This is the first randomised control trial in children to investigate the use of peripherally 
applied opioids in children. It is also larger than the few similar trials, which have been 
performed, in the adult population (Zeppetella et al 2003; Flock et al 2003).
The benefits of topical morphine providing pain relief, are most evident in reduction of 
background pain, which is often the most difficult to control in this patient group. 
However I noted a number of difficulties/pitfalls surrounding the trial design noted 
whilst conducting this trial, which I will discuss in the next chapter.
CHAPTER 5: CONCLUSION
Linking the two trials: Pitfalls noted during the studies: Future research.
Although my work consisted of two entirely different projects, this concluding chapter 
explains how the results of the laboratory study provide a basis for the clinical use of 
topical opioids. I will explain the association between the two projects. I will also 
discuss what the next stage should be in the laboratory work, in order to provide further 
crucial information. I will explore what pitfalls I have noted in the trial design of the 
clinical study and how the design could be improved, as well as what future clinical 
research should be carried out.
5.1 LINKING THE TWO TRIALS
The results I obtained following my laboratory work provided me with ideas of how to 
proceed with the clinical work. The fact that I detected the presence of MOR in 
neonatal, infant and young adult rat skin and that these receptors were regulated not 
only throughout development but also following a painful inflammatory stimulus, led 
me to concur that human infants and young people may indeed also possess identical 
receptors with similar properties.
I hypothesised that in accordance with the finding of the animal studies, MOR existed in 
the skin of human infants and children and therefore the application of peripheral 
morphine to the skin would be efficacious and regulated throughout development and 
post inflammation.
It is known that following neonatal cutaneous skin wounding such as a noxious 
inflammatory insult, there is hyperinnervation of the affected and surrounding skin 
tissue, leading to a greater number of peripheral sensory nerves sprouting up to the 
epidermis, in response to increasing nerve growth factor levels (NGF)(Reynolds et al 
1997). This injury is thought to reduce pain thresholds and so produce a heightened pain 
response (hyperalgesia as well as allodynia in later life), as confirmed in a series of 
clinical trials by Taddio (Taddio et al 1997).
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Therefore, infants and children with a diagnosis of EB, who are known to be susceptible 
to painful skin injury in the early neonatal period or even intrauterine period, should 
have hyperinnervation of the cutaneous sensory neurons in the skin of the affected and 
surrounding area based on the above research. Subsequently as the quantity of sensory 
neurons increase post inflammation, the quantity of MOR will also increase, as they are 
positioned on the peripheral sensory neurons (Stein 1993; Stander et al 2002). Also it is 
also known that MOR effects are enhanced during inflammation most likely secondary 
to perineural membrane disruption. The membrane is disrupted in early inflammation 
(Antonijevic et al 1995) and so provides evidence for the efficacy of peripherally 
applied morphine in disorders such as EB, where there are painful inflammatory lesions, 
thus enabling access of the topical morphine via the disrupted perineurium and 
interaction with MOR which are situated on the sensory neuron.
Therefore, in summary, following a painful inflammatory insult in skin tissue, there will 
be a proportionally increased efficacy of peripheral opioids for the following reasons;
a) Hyperinnervation of region due to up-regulation of sensory neurons (Reynolds et al 
1997)
b) Proportional increase in MOR which are situated on the sensory neurons (Stander et 
al 2002)
c) Perineural disruption allowing ease of opioid binding (Antonijevic et al 1995).
5.2 FURTHER LABORATORY STUDIES REQUIRED
The laboratory study demonstrated via direct immunofluroescence, the presence of mu 
opioid receptors (MOR) in cutaneous tissue of neonatal, infant and young adult rat 
models. The study also proved that there was significantly more staining for MOR in 
the youngest animals and post inflammation and this was postnatally regulated. This is 
in keeping with the postnatal regulation of central MOR, which have found to be 
located on cells of dorsal root ganglia (DRGs) of all diameter size in the first 3 weeks 
of life, but persist on the largest diameter cell bodies of the Ap fibres in the youngest 
animals (Beland and Fitzgerald 2001 ).
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These are the sensory neurons, which are sensitive to innocuous stimuli but in rat pups 
these neurons respond to both noxious and innocuous stimuli, thus further 
distinguishing between opioid function in the adult and in the immature central nervous 
system.
Again a significant number of these MOR expressed centrally on DRG neurons have 
been shown by calcium imaging to be more functional in the neonate rat in comparison 
to the adult (Nandi et al 2004).
Western blot analysis in my work, quantified the MOR protein levels and again 
demonstrated two distinct bands; the 50kd band expressed significantly in the younger 
age group and the total protein levels increased following inflammation. Interestingly 
this correlates with the changing receptor profile throughout development. I will now 
note the problems detected with the laboratory study with suggested follow up work.
Problem 1: Detection of precise location of opioid receptors. The exact location of 
the receptors was not investigated in this study but it was assumed that they would be 
located on the sensory nerve fibres, as well as the keratinocytes or immunocytes in the 
epidermis, dermis or sub-epidermal region, as previously demonstrated in adult human 
tissue from patients with atopic dermatitis and psoriasis (Stander et al 2002).
Follow on study required. The precise location should be demonstrated in neonatal 
and infant rat pups as a follow up study, using double immunofluroescence with MOR 
and a pan neuronal antibody such as PGP 9.5 or NF200, to demonstrate co-localisation 
both with and without and a post inflammatory insult such as carageenan.
Problem 2: Clinical effect of topical morphine in rat pups was not tested. Direct 
application of topical morphine was not tested on the rat pups due to time constraints 
and would have provided beneficial parallel information
Follow on study required. Further laboratory work should focus on application of the 
topical morphine to various ages of rat pups with an inflammatory wound and by using 
the techniques of electrophysiology/behavioural testing identification of the effects of 
the topical morphine at different ages.
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Problem 3: No investigation of mRNA. Further work would help identify whether 
there is a similar biphasic up-regulation of m RNA for MOR in the neonatal and infant 
rat pup which has been studied in the adult rat model (Puehler et al 2004).
Follow on study required. This would involve performing Polymerase Chain Reaction.
5.3 FURTHER CLINICAL TRIALS REQUIRED
I noted a number of problems with the trial design on completion of the study which I 
would now like to highlight and then describe suggestions for future trials which could 
perhaps overcome these problems.
Problem 1: Application of morphine gel in those who have daily versus less 
frequent dressing changes was not trialled separately. It is not appropriate to 
compare analgesic effect of topical morphine for those who had daily dressings, versus 
those who had less frequent dressings, e.g. the same application of gel remained on 
some patients up to 4 days in those who had twice weekly dressings.
Follow on study required. Conduct separate trials to distinguish analgesic effect within 
groups who have same frequency of dressing changes per week.
Problem 2: No range of different doses trialled. Only one dose was trialled in this 
study and it would be worthwhile to repeat, using a range of doses, especially as the one 
dose was used on all sizes of lesions and it may be that larger lesions may in fact absorb 
the topical morphine more quickly than smaller lesions, therefore requiring a smaller 
dose or conversely larger lesions may require larger doses to achieve equitable analgesia 
to those with smaller lesions.
Follow up study required. Perform dosing studies using a range of doses and analyse 
against size of lesion.
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Problem 3: The action of Intrasite gel was not separately studied on the skin 
lesions and may contribute to healing of skin lesions. It is unclear what action 
Intrasite gel alone may have had, if any upon the lesions in this patient group. A 
previous smaller RCT in adults used Intrasite gel as the placebo and showed that 
analgesia was not achieved when it was applied to painful ulcers, whilst the topical 
application of diamorphine gel/Intrasite gel resulted in significant pain relief (Flock 
2003).
Further study required. It would be useful to have had a third arm in the trial using 
Intrasite gel alone and assessing analgesic effect. It would be also useful to identify 
during this work whether healing is occurring in either the Intrasite or topical morphine 
or even placebo arms of the trial.
Problem 4: There was no continuous documentation of concurrent use of analgesia 
throughout trial. This particular study did not specifically evaluate the concurrent use 
of the patients’ usual analgesia as a confounding variable, as there was no significant 
difference in the amount of opioids/NSAIDs/or paracetamol used by patients in the two 
treatment arms. In my study, the patients continued taking their prescribed systemic 
analgesics when required.
Follow on study required. An essential follow on trial would be to analyse data on 
analgesic consumption throughout, to determine if similar results to my RCT would 
have been documented. One case study has demonstrated that topical morphine is best 
used as an adjunct rather than the sole analgesic in painful skin lesions (Tran and 
Fancher 2007).
Problem 5: There was no precise identification of the mode of action of peripheral 
morphine in the subjects in this study. Although my trial assumed that topical 
morphine acts on the peripheral opioid receptors as has been demonstrated in the adult 
population (Stein et al 2003), it was not proven in the paediatric patients studied in this 
trial.
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Follow on study required. The detection of morphine and/or its metabolites in serum 
samples would be very useful to explore, even though studies in infants and children 
have verified that there is little correlation between systemic (although not peripheral) 
absorption and clinical effect (Bouwmeester et al 2004; Hansen et al 1996).
My research period did not allow time for this to be investigated but it is also very 
difficult to obtain serum samples from this patient group, as the fragility of their skin 
often prevents a straightforward venepuncture and so they become very needle phobic. 
Laboratory examination in the skin tissue of the patients for the actual presence, exact 
location and proposed up-regulation following painful inflammation would have 
provided exciting information to confirm the hypothesis.
Problem 6: Length of treatment arms. The length of each treatment arm may have 
been too long, and in fact the initial painful lesion may have begun to heal or in fact 
may have completely healed, thus allowing the researcher to have made inaccurate 
conclusions regarding the effect of the topical treatments.
The patients and their families in some incidences may also became uninterested in 
accurately completing the necessary dairy sheets.
Further study required It may have been more suitable to have shortened the 
treatment arm from two weeks to one week each with a few days washout period in 
order to avoid possible healing of lesions.
5.4 CONCLUDING REMARKS AND FUTURE RESEARCH
Although there are limitations in both my laboratory and clinical work I have attempted 
to contribute to pain research in children by investigating the presence of peripheral 
opioids in neonatal animal models and the effect of developmental regulation as well as 
any effect following a painful inflammatory insult. Although by no means ideal I have 
extrapolated the results form my laboratory work to propose that similar findings may 
exist in a human model of inflammatory pain along with similar developmental 
regulation. In this preliminary clinical work, I have provided initial evidence for clinical 
efficacy of this novel route of morphine in children particularly in background pain.
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There should of course be further trials as suggested above, to clarify the precise 
mechanism and in what situations this route of morphine, may be most beneficially used 
in paediatric patients.
In conclusion, topical morphine may perhaps be used, most likely as an adjunct to 
conventional analgesia in order to manage background cutaneous inflammatory pain 
and following further research, may even in the be beneficial in a variety of other 
paediatric diagnoses where background pain is problematic, for example in post 
operative wounds, in bums, in ulcerating vascular haemangiomas or ulcerating tumours 
and in pressure ulcers.
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My Pain Diary
Please fill In a new pain diary everyday.
The best time is one hour after your dressing change.
My name ...................................................................................
Which gel mixture is being used A or B (please circle) 
©  What time was my dressing changed ....................  D ate ....................
©
My pain one hour 
after dressing changed
My pain for the 
last 24 hours
My mobility over the 
last 24 hours
Draw a cross on the line showing how much pain you have 
0 10
no pain worst pain
Draw a cross on the line showing how much pain you have 
0 10
no pain worst pain
0 My mood over the 
last 24 hours
©  My quality of sleep over 
the last 24 hours
Draw a cross on the line showing how easy it is for you to move
0  10
no problem worst possible
Draw a cross on the line showing how you are feeling
10
happy
Draw a cross on the line to show how you are sleeping
best sleep
saddest
 10
no sleep
0  Did any special events happen today?
Did any of these happen to you today which 
may have effected your pain?
(please *)
> an accident / or fall
> a skin infection
> any other illness eg. a cold
> sports day or extra activity
^  Other (if Yes'please write below)
©  Did I have any of these 
symptoms today?
(please S)
> nausea
> vomiting
> constipation
>  drowsiness
> itching
^  Other (if Yes'please write below)
Brief Pain Inventory (Short Form)
Date Time
Name
1. ♦ On the diagram, shade in the areas where you feel pain. 
Mark the area where the gel is.
RightRight Left Left
2. Please rate your pain by circling the one number that best describes your pain when it was 
at its WORST in the last week
No pain 0 1  2 3 4 5 6 7 8 9  10 Pain as bad as you
can imagine
3. Please rate your pain by circling the one number that best describes your pain when it was 
at its LEAST in the last week
No pain 0 1  2 3 4 5 6 7 8 9  10 Pain as bad as you
can imagine
4. Please rate your pain by circling the one number that best describes your pain on the 
AVERAGE
No pain 0 1  2 3 4 5 6 7 8 9  10 Pain as bad as you
can imagine
5. Please rate your pain by circling the one number that tells how much pain you have
RIGHT NOW
No pain 0 1  2 3 4 5 6 7 8 9  10 Pain as bad as you
can imagine
6. What other treatments or medications are you receiving for your pain?
7. Circle the one number that describes how, during the last week, pain has INTERFERED with
your:
Does not interfere 0 1 2  3 4 5 6 7 8 9 10 Completely interferes
Does not interfere 0 1 2  3 4 5 6 7 8 9 10 Completely interferes
Does not interfere 0 1 2  3 4 5 6 7 8 9 10 Completely interferes
Does not interfere 0 1 2  3 4 5 6 7 8 9 10 Completely interferes
Does not interfere 0 1 2  3 4 5 6 7 8 9 10 Completely interferes
Does not interfere 0 1 2  3 4 5 6 7 8 9 10 Completely interferes
G. ENJOYMENT OF LIFE
Does not interfere 0 1  2 3 4 5 6 7 8 9 1 0  Completely interferes
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